Pharmacological and Toxicological Studies of Methanolic Extract of *Mikania cordata*

This Thesis Paper Submitted in Partial Fulfillment of the Requirement for the Degree of Masters of Pharmacy, East West University

Submitted by

Sweety Ritchil ID: 2014-1-79-029

Supervised by Dr. Shamsun Nahar Khan Ph. D, Postdoc, Harvard University Chairperson Department of Pharmacy East West University

Submission Date: 30th July, 2016



This Research paper is dedicated to my beloved Parents

DECLARATION BY THE CANDIDATE

I hereby declare that this dissertation, entitled "**Pharmacological and Toxicological studies of Methanolic Extract of** *Mikania cordata*" is an authentic and genuine research work carried out by me under the guidance of Dr. Shamsun Nahar Khan, Chairperson, Department of Pharmacy, East West University, Dhaka.

Sweety Ritchil ID # 2014-1-79-029 Department of Pharmacy East West University, Dhaka.

ENDORSEMENT BY HEAD OF THE DEPARTMENT

This is to certify that the dissertation entitled "**Pharmacological and Toxicological studies of Methanolic Extract of** *Mikania cordata*" is a genuine research work carried out by Sweety Ritchil, under the supervision of Shamsun Nahar Khan (Ph. D, Postdoc, Harvard University, Chairperson, Department of Pharmacy, East West University, Dhaka). I further certify that no part of the thesis has been submitted for any other degree and all the resources of the information in thus connection are duly acknowledged.

Dr. Shamsun Nahar Khan Ph. D, Postdoc, Harvard University Chairperson Department of Pharmacy East West University

CERTIFICATE

This is to certify that, the thesis on "**Pharmacological and Toxicological studies of Methanolic Extract of** *Mikania cordata* " submitted to Department of Pharmacy, East West University, Aftabnagar, Dhaka, in partial fulfillment of the requirements for the degree of Masters of Pharmacy (M. Pharm), was carried out by Sweety Ritchil (ID # 2014-1-79-029) under my guidance and supervision and that no part of the thesis has been submitted for any other degree. We further certify that all the sources of information of in this connection are duly acknowledged.

Dr. Shamsun Nahar Khan Ph. D, Postdoc, Harvard University Chairperson Department of Pharmacy East West University Aftabnagar, Dhaka

ACKNOWLEDGEMENT

Above all, I express my gratitude to Almighty Allah for giving me the strength, energy and patients to carry out this research work. I would like to express my gratitude and admiration to **Dr. Shamsun Nahar Khan**, Associate Professor and Chairperson, Department of Pharmacy, East West University, for his suggestion, careful guidance, sincere help, constructive criticism and valuable time without which I would not have been able to complete this work. He had been very enthusiastic and supportive in my research.

I would like to convey deepest love and obedience to my parents for their support, inspiration and guiding me all through my life until today, which keeps me strong and firm to do the things I needed to do.

I would also like to take the opportunity to express my whole hearted gratitude to my fellow researcher friends specially Nusrat Jahan, Fatema Akther, Mohammad Ali and near and dear ones who offered encouragement, information, inspiration and assistance during the period of constructing the research report.

I am thankful to the laboratory instructors for their kind support during the laboratory work.

ABSTRACT

Purpose: The research work was carried out to determine the pharmacological activities of methanolic extract of *Mikania cordata*.

Method: Methanolic extract was administered orally to the animal model (*Swiss albino*) and the effects were determined by comparing with respect to control group which were treated with 5% CMC. For every experiment positive control was used. Different experiments were used to determine the pharmacological profile which was collected from internationally published publications and journals.

Result: The CNS activity was evaluated by open field method and hole board test. In the open field method and hole board experiment the crude extract of *Mikania cordata*. (200mg/kg, & 400mg/kg) dose dependently reduces the number of peripheral locomotion, central locomotion and leaning in the open field test and reduces the number of head dipping and head poking in the hole board test. The reduction is significant when it is compared to the standard drug.

The aim of the study was also to investigate the possible toxicity of the plant *Mikania cordata* and especially to establish the safety of the methanolic extract of this plant by focusing on its chronic toxicity in mice. For finding chronic toxicity several tests are done such as CBC (Cell Blood count) test and Hepatic enzyme test.

All data were analyzed by using SPSS analytical method.

Conclusion: After summarize all the results it can say that *Mikania cordata* may have several pharmacological activities but to prove the hypothesis it need further higher studies.

Keywords: Mikania cordata, Neuropharmacological effect and Toxicity test.

Table of Contents

Chapter 1

| Introduction | n 1-28 |
|--------------|--|
| 1.1 Med | icinal Plant 1 |
| 1.1.1 | Definitions of medicinal plants 1 |
| 1.1.2 | Importance of Medicinal Plant 2 |
| 1.1.3 | Medicinal plants & Traditional Medicine Practice in Bangladesh 2 |
| 1.1.4 | Nervous System 3 |
| 1. | .1.4.1 The central Nervous System 4 |
| 1. | .1.4.2 Parts of Central Nervous System |
| 1. | .1.4.3 Peripheral Nervous System |
| 1. | .1.4.4 Nerve cells |
| 1. | .1.4.5 Synapse |
| | Different Central Nervous System Disorders9 |
| 1.2 Toxic | city aspects of use of herbal preparations |
| 1.2.1 | Causes of toxicity with herbal products 10 |
| 1.2.2 | Toxicology 11 |
| 1.2.3 | Toxicity 11 |
| 1.2.4 | Exposure 11 |
| 1.2.5 | Route of Exposure 11 |
| 1.2.6 | Acute toxicity |
| 1.2.7 | Chronic toxicity |
| 1.2.8 | Evaluation of herbal toxicity 12 |
| 1.3 Hem | atology 13 |
| 1.3.1 | Cellular Elements of Blood |
| 1.3.2 | Plasma14 |
| 1.3.3 | Cellular Elements |
| 1. | .3.3.1 Red Blood Cell 15 |
| 1. | .3.3.2 White Blood Cell |
| 1. | .3.3.3 Platelets |
| | |

| 1.4 Hepatotoxicity2 | 23 |
|--|--|
| 1.4.1 Liver | 24 |
| 1.4.2 Liver function tests | 25 |
| 1.4.2.1 Albumin | 26 |
| 1.4.2.2 Alkaline phosphatase 2 | 27 |
| 1.4.2.3 Aspartate transaminase 2 | 27 |
| 1.4.2.4 SGPT test | 28 |
| Chapter 2 | |
| Introduction of Plant29- | -36 |
| | |
| 2.1 Introduction of Plant, <i>Mikaniacordata</i> 2 | 29 |
| 2.1 Introduction of Plant , <i>Mikaniacordata</i> 2 2.1.1 Description of Mikaniacordata 2 | |
| | 30 |
| 2.1.1 Description of Mikaniacordata | 30 30 |
| 2.1.1 Description of Mikaniacordata. 3 2.1.1.1 Scientific name. 3 | 30 30 30 |
| 2.1.1 Description of Mikaniacordata. 3 2.1.1.1 Scientific name. 3 2.1.1.2 Local name. 3 | 30 30 30 30 |
| 2.1.1 Description of Mikaniacordata. 3 2.1.1.1 Scientific name. 3 2.1.1.2 Local name. 3 2.1.1.3 Taxonomic position. 3 | 30 30 30 30 30 30 |
| 2.1.1 Description of Mikaniacordata. 3 2.1.1.1 Scientific name. 3 2.1.1.2 Local name. 3 2.1.1.3 Taxonomic position. 3 2.1.1.4 Description. 3 | 30 30 30 30 30 30 31 |
| 2.1.1 Description of Mikaniacordata.32.1.1.1 Scientific name.32.1.1.2 Local name.32.1.1.3 Taxonomic position.32.1.1.4 Description.32.1.2 Habitat/ecology.3 | 30 30 30 30 30 30 31 31 |

Chapter 3

| Materials and Methods 3 | 9-47 |
|--|------------|
| 3.1 Plant Preparation | . 39 |
| 3.1.1 Collection of plant | 39 |
| 3.1.2Preparation of plant extraction | . 39 |
| 3.2 Experimental Animals | 41 |
| 3.3 CNS Activity Test | 41 |
| 3.3.1 Materials for CNS Activity Test | 41 |
| 3.3.2 Standard Drugs Used in CNS activity Test | 42 |
| 3.3.2 Doses Used in CNS Activity Test of the Extract | . 43 |
| 3.3.3 Methods for CNS Activity Test | 44 |

| 3.4. Toxicity Test | 45 |
|--|----|
| 3.4.1 Materials for Toxicity Test | 45 |
| 3.4.2 Chemical Agents Used Toxicity Test | 45 |
| 3.4.3 Doses Used for Toxicological Activity of the Extract | 45 |
| 3.4.4. Hematological parameters | 46 |
| 3.4.5. Serum biochemical parameters | 46 |
| 3.4.6. Histopathological studies | 47 |
| 3.5. Statistical Analysis | 47 |

Chapter 4

| Results and Discussion | -62 |
|--|-----|
| 4.1 CNS Activity Test of Methanolic Extract of <i>Mikaniacordata</i> | 47 |
| 4.1.1 Open Field Test | 47 |
| 4.1.2 Hole Board Test | 54 |
| 4.4. Chronic Toxicity Test | 55 |
| 4.4.1 Chronic Toxicity Test | 55 |
| 4.4.2.1 CBC Test, Biochemical Test & Histological Studies | 55 |
| 4.4.3. Abnormalities | 62 |

Chapter 5

| Conclusion | 64 |
|------------|------|
| Reference | 6569 |
| Annexure | 70 |

List of Figures

| Figure No. | | Page |
|------------|---|------|
| | | No. |
| Figure:1 | Organization of the Human Nervous System | 4 |
| Figure:2 | Central Nervous System | 5 |
| Figure:3 | Human Brain | 6 |
| Figure:4 | Neuron | 7 |
| Figure:5 | Plasma of the Blood | 14 |
| Figure:6 | Red Blood Cell & Hemoglobin | 15 |
| Figure:7 | Different Parts of White Blood Cell and Platelet | 22 |
| Figure:8 | Anatomy of liver | 24 |
| Figure:9 | Whole Plant of Mikaniacordata | 29 |
| Figure:10 | Herbarium sheet of Mikaniacordata | 39 |
| Figure:11 | Rotary evaporator & crude extract in a bottle | 40 |
| Figure:12 | Swiss albino Mice | 41 |
| Figure:13 | Open Field Test | 43 |
| Figure:14 | Hole Board Test | 44 |
| Figure:15 | Graphical Presentation of CNS Activity of plant extract of | 51 |
| | Mikaniacordataby Open Field Test (Peripheral Locomotion) in Mice | |
| Figure:16 | Graphical Presentation of CNS Activity of plant extract of | 50 |
| | Mikaniacordataby Open Field Test (Central Locomotion) in Mice | |
| Figure:17 | Graphical Presentation of CNS Activity of plant extract of Mikaniacordata | 52 |
| | by Open Field Test (Leaning) in Mice | |
| Figure:18 | Graphical Presentation of CNS Activity of plant extract of Mikaniacordata | 55 |
| | by Hole Board Test in Mice | |
| Figure:19 | Graphical Presentation of Effect of methanolic extract of Mikaniacordata | |
| | on body weight in mice | |
| Figure:20 | Effect of Mikaniacordata on the Different count of WBC (White Blood | 56 |
| | Cell) | |

| Figure:21 | Effect of Mikaniacordata on the different count of RBC (Red Blood Cell) | 57 |
|-----------|---|----|
| Figure:22 | Effect of Mikaniacordata on Platelet on the CBC (Count Blood Cell) Test | 58 |
| Figure:23 | Effect of Mikaniacordata on the Liver Function Test | 59 |
| Figure:24 | Eye problem of mice | 62 |
| Figure:25 | Tumor of mice | 62 |

List of Tables

| | Table No. | Page No. |
|----------|---|----------|
| Table:1 | Reference value of different protein that distinguish the liver disorders | 23 |
| Table:2 | Different isolated compound in different parts of Mikania Cordata | 32 |
| Table:3 | CNS Activity of plant extract of Mikaniacordata by Open Field Test | 83 |
| | (Peripheral Locomotion) in Mice | |
| Table:4 | CNS Activity of plant extract of Mikaniacordata by Open Field Test | 85 |
| | (Central Locomotion) in Mice. | |
| Table:5 | CNS Activity of plant extract of Mikaniacordata by Open Field Test | 87 |
| | (Leaning) in Mice. | |
| Table:6 | CNS Activity of plant extract of Mikaniacordata by Hole Board Test in | 90 |
| | Mice. | |
| Table:7 | Analgesic Activity of plant extract of Mikaniacordata by Acetic Acid | 93 |
| | Induced Writhing test in Mice. | |
| Table:8 | Analgesic Activity of Plant Extract of Mikaniacordata in Formalin | 99 |
| | Induced Hind Paw Licking in Mice | |
| Table:9 | Analgesic Activity of plant extract of Spilanthesacmella by Acetic Acid | 106 |
| | Induced Writhing test in Mice | |
| Table:10 | Analgesic Activity of plant extract of Spilanthesacmella in Formalin | 111 |
| | induced hind paw licking in mice. | |
| Table:11 | Effect of methanolic extract of Mikaniacordata on body weight in mice | 116 |
| Table:12 | Effect of Mikaniacordata on the count of WBC (White Blood Cell) | 118 |
| Table:13 | Effect of Mikaniacordata on the count of RBC (Red Blood Cell) | 119 |
| Table:14 | Effect of Mikaniacordata on Platelet count on the CBC (Count Blood | 120 |
| | Cell) Test | |
| Table:15 | Effect of Mikaniacordata on the Liver Function Test | 121 |
| Table:16 | CBC and biochemical parameters of tumor mice | 124 |

Chapter 1 Introduction

1. Introduction

1.1 Medicinal Plant

Throughout history plants have been used by human beings for medicinal purposes and even in modern times have formed the basis of many pharmaceuticals in use (Schmidt et. al.,2008). The medicinal use of plants is probably as old as mankind itself. Plants have continued to be a valuable source of natural products for maintaining human health, as studies on natural therapies have intensified. More than 150,000 plant species have been studied, and several of them contain therapeutic substances. A recent review has shown that approximately 25% of modern medications have been plant derived, while 75% of new drugs against infectious diseases that have arrived between 1981 and 2002 originated from natural sources (Bedoya et.al.,2009) The use of plant compounds for pharmaceutical purposes has gradually increased. According to the World Health Organization medicinal plants are probably the best source of a variety of drugs. About 80 % of individuals in developed countries use traditional medicine containing compounds derived from medicinal plants (Varalakshmi et.al., 2011). People using only allopathic medicine throughout their lives are likely to be somewhat medicinal plant reliant as 20-25% of drugs prescribed are plant derived (Hall et.al., 2012).

1.1.1 Definitions of medicinal plants

A considerable number of definitions have been proposed for medicinal plants. According to the WHO, "A medicinal plant is any plant which, in one or more of its organs, contains substances that can be used for therapeutic purposes, or which are precursors for chemo-pharmaceutical semi-synthesis." When a plant is designated as 'medicinal', it is implied that the said plant is useful as a drug or therapeutic agent or an active ingredient of a medicinal preparation. "Medicinal plants may therefore be defined as a group of plants that possess some special properties or virtues that qualify them as articles of drugs and therapeutic agents, and are used for medicinal purposes" (Ghani, 2003).

1.1.2 Importance of Medicinal Plant

Plants are the tremendous source for the discovery of new products with medicinal importance in drug development. Today several distinct chemicals derived from plants are important drugs, which are currently used in one or more countries in the world. Herbal medicines have been utilized for many purposes, particularly in medical care as antiasthmatics (86.79 %), anti-rheumatics (62 %), diuretics (60.22 %), antiinflammation (29.62 %), anticancer (9.75 %), antidiabetics (8.33 %), antimicrobials, antifungals, antioxidants, antiallergy, analgesics, antiobesity and antihypertention. In dental care it has been employed as anticariogenic, analgesic, local anesthetic, wound healing agents, anti-inflammation and recurrent aphthous stomatitis treatment etc. Based on their biosynthetic origins, plant natural products can be divided into three major groups: the terpenoids, the alkaloids, and the phenolic compounds. All terpenoids, including both primary metabolites and more than 25,000 secondary compounds, are derived from the five-carbon precursor isopentenyl diphosphate (IPP). The 12,000 or so known alkaloids, which contain one or more nitrogen atoms, are biosynthesized principally from amino acids. The 8000 or so phenolic compounds are formed by way of either the shikimic acid pathway or the malonate/acetate pathway (Ghani, 2003).

1.1.3 Medicinal plants & Traditional Medicine Practice in Bangladesh

The plants which are useful for healing several diseases are called medicinal plant. There are 722 medicinal plants in our country. Bangladesh possesses a rich flora of medicinal plants. Out of the estimated 5000 species of different plants growing in this country more than a thousand are regarded as having medicinal properties. Out of them, more than a thousand have been claimed to posses medicinal poisonous properties, of which 546 have recently been enumerated with their medicinal properties and therapeutic uses. In addition to possessing various other medicinal properties, 257 of these medicinal plants have been identified as efficacious remedies for diarrhoeal diseases and 47 for diabetes (Ghani, 2003).

Traditional medical practice among the tribal people is mainly based on the use of plant and animal parts and their various products as items of medicine. The medicaments, prepared from plant materials and other natural products sometimes also include some objectionable substances of animal origin. They are dispensed in a number of dosage forms like infusions, decoctions, pastes, moulded lumps, powders, dried pills, creams and poultices. Diets are strictly regulated .Since indigenous peoples have a long history and expertise in the use of medicinal plants, it is impotant that their plant usage be documented as the basis for the development of lead compounds before this knowledge is lost due to the influences of modern civilization. Bangladesh has a number of indigenous people or tribes including the Chakmas, Garos, Santals, Marmas, Tripuras and others.(Hussain et.al, 2012)

1.1.4. Nervous System

The human nervous system is perhaps the most complex system of any organism. The nervous system consists of the brain, spinal cord, sensory organs, and all of the nerves that connect these organs with the rest of the body. Together, these organs are responsible for the control of the body and communication among its parts. The human brain alone contains over 100 billion nerve cells, and each nerve cell can have up to 10,000 connections to other nerve cells. This means that a nerve impulse—an electrochemical signal to or from the brain could travel along 10¹⁵ possible routes. The nervous system has two major divisions: the central nervous system (CNS) and the peripheral nervous system (PNS). The brain and spinal cord form the control center known as the central nervous system (CNS), where information is evaluated and decisions made. The sensory nerves and sense organs of the peripheral nervous system (PNS) monitor conditions inside and outside of the body and send this information to the CNS. Efferent nerves in the PNS carry signals from the control center to the muscles, glands, and organs to regulate their functions.




Figure-1: Organization of the Human Nervous System.

1.1.4.1. The central Nervous System

The "Central Nervous System", comprised of brain, brainstem, and spinal cord. The central nervous system (CNS) represents the largest part of the nervous system, including the brain and the spinal cord. Together, with the peripheral nervous system (PNS), it has a fundamental role in the control of behavior. The CNS is conceived as a system devoted to information processing, where an appropriate motor output is computed as a response to a sensory input. CNS is protected by Bone (skull, vertebrae). They are also wrapped up in three protective membranes called meninges (spinal meningitis is infection of these membranes). Spaces between meninges filled with cerebrospinal fluid for cushioning and protection. This fluid also found within central canal of the spinal cord and ventricle of brain. (Kandel et.al,. 2000)




Figure-2: Central Nervous System

1.1.4.2. Parts of Central Nervous System

- Brain
- Medulla
- Pons
- Cerebrum
- Cerebellum
- Spinal cord




Figure-3: Human Brain

1.1.4.3. Peripheral Nervous System:

The peripheral nervous system includes nerves that carry sensory messages to the central nervous system and nerves that send information from the CNS to the muscles and glands. The peripheral nervous system is further divided into the somatic system and the autonomic system. The peripheral nervous system includes 12 cranial nerves 31 pairs of spinal nerves. Somatic nervous system and Autonomic nervous system are the part of peripheral nervous system.

Somatic Nervous System: The somatic system consists of nerves that carry sensory information to the central nervous system, and nerves that carry instructions from the central nervous system to the skeletal muscles.

Autonomic Nervous System: The autonomic system controls glandular secretions and the functioning of the smooth and cardiac muscles. The sympathetic and parasympathetic divisions of the autonomic system often work in opposition to each other to regulate the involuntary processes of the body. Involuntary processes, such as heartbeat and peristalsis, are those that do not require or involve conscious control.

1.1.4.4. Nerve cells

Neurons or nerve cells carry out the functions of the nervous system by conducting nerve impulses. They are highly specialized. If a neuron is destroyed, it cannot be replaced because neurons do not go through mitosis. Each neuron has three basic parts like, cell body (soma), one or more dendrites, and a single axon.




Figure-4: Neuron

Cell Body or Soma:

In many ways, the cell body is similar to other types of cells. It has a nucleus with at least one nucleolus and contains many of the typical cytoplasmic organelles. It lacks centrioles. Because centrioles function in cell division, the fact that neurons lack these organelles is consistent with the amitotic nature of the cell. It is the metabolic center of the neuron. It gives rise to further two processes, dendrites and axon.

Axon:

Cell body gives rise to a tubular process which is the main conducting unit of the neuron, capable of conveying information at great distances by propagating transient electrical signal called action potential. Many axons are surrounded by a segmented, white, fatty substance called myelin or the myelin sheath. Myelinated fibers make up the white matter in the CNS, while cell \bodies and unmyelinated fibers make the gray matter. The unmylinated regions between the myelin segments are called the nodes of ranvier. Thus, axons are of two types, myelinated and non-myelinated.

Dendrites:

Dendrites and axons are cytoplasmic extensions, or processes, that project from the cell body. They are sometimes referred to as fibers. Dendrites are usually short and branching, which increases their surface area to receive signals from other neurons. The number of dendrites on a neuron varies (Martini et.al, 2003).

1.1.4.5. Synapse

The synapse is a small gap separating neurons. The synapse consists of a presynaptic ending that contains neurotransmitters, mitochondria and other cell organelles, a postsynaptic ending that contains receptor sites for neurotransmitters and a synaptic cleft or space between the presynaptic and postsynaptic endings. It is about 20nm wide.

1.1.4.6. Different Central Nervous System Disorders

- ✓ Alzheimer's disease-A progressive, degenerative disease that occurs in the brain and results in impaired memory, thinking, and behavior.
- ✓ Bradykinesia- Slowness of movement.
- ✓ **Bradyphrenia**-Slowness of thought processes
- ✓ Cerebral embolism- A brain attack that occurs when a wandering clots (embolus) or some other particle forms in a blood vessel away from the brain - usually in the heart.
- ✓ Cerebral hemorrhage- A type of stroke occurs when a defective artery in the brain bursts, flooding the surrounding tissue with blood.
- ✓ Cerebral thrombosis- The most common type of brain attack; occurs when a blood clot (thrombus) forms and blocks blood flow in an artery bringing blood to part of the brain.
- ✓ Delusions- A condition in which the patient has lost touch with reality and experiences hallucinations and misperceptions.
- ✓ Dementia- It is not a disease itself, but group of symptoms that characterize diseases and conditions; it is commonly defined as a decline in intellectual functioning that is severe enough to interfere with the ability to perform routine activities.
- ✓ **Epilepsy** (Also called seizure disorder)-A brain disorder involving recurrent seizures.
- ✓ **Euphoria** A feeling of well-being or elation; may be drug-related.
- ✓ Guillain-Barré syndrome- A disorder in which the body's immune system attacks part of the nervous system.
- ✓ Headache (primary)-Includes tension (muscular contraction), vascular (migraine), and cluster headaches not caused by other underlying medical conditions.
- ✓ Headache (secondary)-Includes headaches that result from other medical conditions. These may also be referred to as traction headaches or inflammatory headaches.
- \checkmark Meningitis-An inflammation of the meninges, the membranes that cover the brain
- ✓ Multiple sclerosis (MS)-A disease of the central nervous system that is an unpredictable condition that can be relatively benign, disabling, or devastating, leaving the patient unable to speak, walk, or write.
- ✓ Parkinson's disease (PD)-The most common form of parkinsonism; a slowly progressing, degenerative disease that is usually associated with the following symptoms, all of which result from the loss of dopamine-producing brain cells: tremor or trembling

of the arms, jaw, legs, and face; stiffness or rigidity of the limbs and trunk; bradykinesia (slowness of movement); postural instability, or impaired balance and coordination.

✓ Seizure- Occurs when part(s) of the brain receives a burst of abnormal electrical signals that temporarily interrupts normal electrical brain function. (Howland and Mycek, 2006).

1.4 Toxicity aspects of use of herbal preparations

Currently, there is an ongoing world-wide "green" revolution which is mainly premised on the belief that herbal remedies are safer and less damaging to the human body than synthetic drugs (Williamson et. al., 1996). Many writers claim that it is assumed that "all things natural are good" (Gaillard and Pepin, 1999) and, generally, the extensive traditional use of herbal products is not assumed to be based on a comprehensive well documented logic, but rather on empirical wisdom accumulated over many years, often arrived at through trial and error and transmitted orally from generation to generation. This traditional methodology has enabled those herbal medicines producing acute and obvious signs of toxicity to be well recognized and their use avoided. However, the premise that "traditional use of a plant for perhaps many hundreds of years establishes its safety does not necessarily hold true". The more subtle and chronic forms of toxicity, such as carcinogenicity, mutagenicity, and hepatotoxicity, may well have been overlooked by previous generations and it is these types of toxicity that are of most concern when assessing the safety of herbal remedies (Williamson *et. al.*, 1996).

1.4.1 Causes of toxicity with herbal products

All chemicals may be considered toxic under certain conditions, e.g. even pure water when inhaled is rapidly absorbed across the lung alveoli to cause lysis of red blood cells. But some chemicals present a greater hazard than others (Pascoe, 1983). A large number of plants contain appreciable levels of biosynthetically produced chemical substances and many of these have either been reported to be toxic to humans or are predictably toxic based on extensive animal or *in vitro* studies (Tomlinson and Akerele, 1998).

Toxicity with medicinal plant products may arise in various ways, but in general two categories of causes can be distinguished:

• In the first category, as previously mentioned, the toxicity may be as a result of exposure to intrinsic ingredients of some medicinal plants. Examples of some more important classes of ingredients implicated here include: *pyrrolizidine alkaloids*, which are said to be hepatocarcinogens; *aristolochic acid I*, said to be mutagenic and carcinogenic; *phorbol esters*, which are tumor promoters and vesicant to the skin; *carboxy actractyloside*, a deadly toxic compound; *amygdalin*, a cyanogenic compound with many undesired effects; etc.. In addition, several studies conducted on flavonoids indicate that, besides their apparently beneficial health effects, they may also induce mutagenicity and genotoxicity (e.g. quercetin) in both bacterial and mammalian experimental systems. (Gaillard and Pepin,1999; Tomlinson and Akerele, 1998)

• The second category of causes of toxicity of herbal medicines is more extrinsic or nonassociated with the plant active constituents. In this category, the toxicity is a result of exposure to plant products contaminated with excessive or banned pesticides, microbial contaminants, heavy metals or chemical toxins, or with substituted ingredients. The pesticide, heavy metal and microbial contaminants may be linked to the source, collection or processing of the herbal materials (e.g.in contaminated environments). (Skibola and Smith, 2000)

1.4.2 Toxicology

Toxicology is a branch of biology, chemistry, and medicine concerned with the study of the adverse effects of chemicals on living organisms. It also studies the harmful effects of chemical, biological and physical agents in biological systems that establish the extent of damage in living organisms. The relationship between dose and its effects on the exposed organism is of high significance in toxicology.

1.4.3 Toxicity

Toxicity is the degree to which a substance can damage an organism. Toxicity can refer to the effect on a whole organism, such as an animal, bacterium, or plant, as well as the effect on a substructure of the organism, such as a cell (cytotoxicity) or an organ such as the liver (hepatotoxicity). By extension, the word may be metaphorically used to describe toxic effects on larger and more complex groups, such as the family unit or society at large.

A central concept of toxicology is that effects are dose-dependent; even water can lead to water intoxication when taken in too high a dose, whereas for even a very toxic substance such as snake venom there is a dose below which there is no detectable toxic effect. Toxicity is species-specific, making cross-species analysis problematic.

1.4.4 Exposure

In order for a chemical to produce a biological effect, it must first reach a target individual. Then the chemical must reach a target site within the body (toxicokinetics). Toxicity is a function of the effective dose of a foreign chemical at its target site, integrated over time. Individual factors such as body weight will influence the dose at the target site.

1.4.5 Route of Exposure

The route (site) of exposure is an important determinant of the ultimate dose. The route of exposure may be important if there are tissue-specific toxic responses. Toxic effects may be local or systemic Different routes may result in different rates of absorption like

- ✓ Dermal (skin)
- ✓ Inhalation (lung)
- ✓ Oral ingestion (Gastrointestinal)
- ✓ Injection (Parenteral)

1.4.6 Acute toxicity

Acute toxicity has been defined as "the ability of a substance to cause severe biological harm or death soon after a single exposure or dose for < 24 h; or any poisonous effect resulting from a single short-term exposure to a toxic substance".

An acute toxicity test is a single test that is conducted in a suitable animal species and may be done for essentially all chemicals that are of any biologic interest. Its purpose is to determine the symptomatology consequent to administration of the compound and to determine the order of lethality of the compound. The test consists of administering the compound to the animals on one occasion (Loomis and Hayes, 1996; Timbrell, 2002).

1.4.7 Chronic toxicity

Chronic toxicity is defined as "the capacity of a substance to cause poisonous health effects in humans, animals, fish and other organisms after multiple exposures occurring over an extended period of time like > 3 months or over a significant fraction of an animal's or human's lifetime. The purpose of the chronic toxicity test is to investigate the harmful effects that foreign compounds that are introduced to animals in repeated doses or in continuous exposure over an extended period of time may produce. The dose levels of compounds used usually range from a very low fraction of the therapeutically effective dose to doses that approach the maximum non-lethal dose (as established in rodent acute toxicity studies) (Poole and Leslie, 1989; Loomis and Hayes, 1996)

1.4.8 Evaluation of herbal toxicity

Herbal toxicity can be evaluated by

(1) observing human or animal populations exposed to the plant material,

(2) administering the plant medicine to animals under controlled conditions and observing the effects (*in vivo*) and

(3) exposing cells, sub-cellularfractions or single-celled organisms to the plant material (*in vitro*)(Timbrell, 2002).

1.5 Hematology

In hematology we deal with the essentials of blood and the tissues for the forming blood. Hematology is used to identify and examine the cure for anemia, leukemia's and hemophilia (a kind of blood disease). Hematological tests are performed to check the results of certain treatments e.g. cancer chemotherapy and also to get outcome about the patients overall health (Ramsay, 1999).

1.5.2 Cellular Elements of Blood

Blood is a circulating tissue composed of fluid plasma and cells (red blood cells, white blood cells, platelets). Anatomically, blood is considered a connective tissue, due to its origin in the bones and its function. Blood is the means and transport system of the body used in carrying elements (e.g. nutrition, waste, heat) from one location in the body to another, by way of blood vessels. (Hajdu, 1998)

Blood is made of two parts:

- 1. Plasma which makes up 55% of blood volume.
- 2. Formed cellular elements (red and white blood cells, and platelets) which combine to make the remaining 45% of blood volume (Alberts, 2012).

1.5.3 Plasma

Plasma is made up of 90% water, 7-8% soluble proteins (albumin maintains bloods osmotic integrity, others clot, etc), 1% carbon-dioxide, and 1% elements in transit. One percent of the plasma is salt, which helps with the pH of the blood. The largest group of solutes in plasma contains three important proteins to be discussed. There are: albumins, globulins, and clotting proteins. Plasma also carries Respiratory gases; CO2 in large amounts (about 97%) and O2 in small amounts (about 3%), various nutrients (glucose, fats), wastes of metabolic exchange (urea, ammonia), hormones, and vitamins.





Figure-8: Plasma of the Blood

1.5.4 Cellular Elements

1.5.4.1 Red Blood Cell

RBCs have a shape of a disk that appears to be "caved in" or almost flattened in the middle; this is called bi-concave. This bi-concave shape allows the RBC to carry oxygen and pass through even the smallest capillaries in the lungs. This shape also allows RBCs to stack like dinner plates and bend as they flow smoothly through the narrow blood vessels in the body. RBCs lack a nucleus (no DNA) and no organelles, meaning that these cells cannot divide or replicate themselves like the cells in our skin and muscles. RBCs have a short life span of about 120 days, however, as long as our myeloid tissue is working correctly, we will produce about 2-3 million RBCs per second. That is about 200 billion a day! This allows us to have more to replace the ones we lose. The main component of the RBC is hemoglobin protein, of which there are about 250 million per cell. The word hemoglobin comes from "hemo" meaning blood and "globin" meaning protein. Hemoglobin is composed of four protein subunits: polypeptide globin chains that contain anywhere from 141 to 146 amino acids. Hemoglobin is responsible for the cell's ability to transport oxygen and carbon dioxide. Normal range of RBC 8-16×106mm3 (Robert, et.al. 2006).






Figure-9: Hemoglobin & Red Blood Cell

Different count of RBC

i. Hemoglobin: Hemoglobin is the iron-containing oxygen-transport metalloprotein in the red blood cells of all vertebrates as well as the tissues of some invertebrates. Hemoglobin in the blood carries oxygen from the respiratory organs (lungs or gills) to the rest of the body (i.e. the tissues) where it releases the oxygen to burn nutrients to provide energy to power the functions of the organism in the process called metabolism.

The hemoglobin test is a commonly ordered blood test and is almost always done as part of a complete blood count (CBC). Common reasons or conditions for ordering the hemoglobin test include:

- Symptoms such as fatigue, feelings of poor health, or unexplained weight loss
- Signs of bleeding are present
- Before and after major surgery
- During pregnancy
- Presence of chronic kidney disease or many other chronic medical problems
- Monitoring of anemia and its cause
- Monitoring during treatment for cancer
- Monitoring medicines that may cause anemia or low blood counts

Normal results for adults vary, but in general are:

- Male: 13.8 to 17.2 grams per deciliter (g/dL)
- Female: 12.1 to 15.1 g/dL

Lower than Normal Hemoglobin

Low hemoglobin level may be due to:

- Anemia due to red blood cells being destroyed earlier than normal (hemolytic anemia)
- Anemia (various types)
- Bleeding from digestive tract or bladder, heavy menstrual periods
- Chronic kidney disease
- Bone marrow being unable to produce new blood cells. This may be due to leukemia, other cancers, drug toxicity, radiation therapy, infection, or bone marrow disorders
- Poor nutrition
- Low level of iron, folate, vitamin B12, or vitamin B6
- Other chronic illness, such as rheumatoid arthritis

Higher than Normal Hemoglobin

High hemoglobin level is most often due to low oxygen levels in the blood (hypoxia), present over a long period of time. Common reasons include:

- Certain birth defects of the heart, present at birth (congenital heart disease)
- Failure of the right side of the heart (cor pulmonale)
- Severe COPD
- Scarring or thickening of the lungs (pulmonary fibrosis) and other severe lung disorders
- A rare bone marrow disease that leads to an abnormal increase in the number of blood cells (polycythemia vera)
- The body not having as much water and fluids as it should (dehydration)

Hematocrit (HCT)

The hematocrit (Ht or HCT, British English spelling haematocrit), also known as packed cell volume (PCV) or erythrocyte volume fraction (EVF), is the volume percentage (%) of red blood cells in blood. It is normally 45% for men and 40% for women. It is considered an integral part of a person's complete blood count results, along with hemoglobin concentration, white blood cell count, and platelet count. Anemia refers to an abnormally low hematocrit, as opposed to polycythemia, which refers to an abnormally high hematocrit. Both are potentially life-threatening disorders (Purves, 2004).

Higher than Normal Hematocrit

- In cases of dengue fever, a high hematocrit is a danger sign of an increased risk of dengue shock syndrome.
- Polycythemia vera (PV), a myeloproliferative disorder in which the bone marrow produces excessive numbers of red cells, is associated with elevated hematocrit.
- Chronic obstructive pulmonary disease (COPD) and other pulmonary conditions associated with hypoxia may elicit an increased production of red blood cells. This increase is mediated by the increased levels of erythropoietin by the kidneys in response to hypoxia.
- Anabolic androgenic steroid (AAS) use can also increase the amount of RBCs and, therefore, impact the hematocrit, in particular the compounds boldenone and oxymetholone.
- If a patient is dehydrated, the hematocrit may be elevated.
- Capillary leak syndrome also leads to abnormally high hematocrit counts, because of the episodic leakage of plasma out of the circulatory system.
- Sleep apnea has been known to cause elevated hematocrit levels.

Lower than Normal Hematocrit

- Infants without adequate iron intake
- children going through a rapid growth spurt, during which the iron available cannot keep up with the demands for a growing red cell mass

- menstruating women, who have a greater need for iron because of blood loss during menstruation
- pregnant women, in whom the growing fetus creates a high demand for iron
- patients with chronic kidney disease whose kidneys no longer secrete sufficient levels of the hormone erythropoietin that promotes RBC proliferation. Erythropoietin prevents the death of cells in the erythrocyte cell line in the bone marrow. Therefore, erythropoietin allows those cells to continue to mature, exit the bone marrow and become RBCs (Jelkmann, 2004).

Mean corpuscular volume, or mean cell volume (MCV)

The mean corpuscular volume, or mean cell volume (MCV), is a measure of the average volume of a red blood corpuscle (or red blood cell). The measure is attained by multiplying a volume of blood by the proportion of blood that is cellular (the hematocrit or haematocrit), and dividing that product by the number of erythrocytes (red blood cells) in that volume. The mean corpuscular volume is a part of a standard complete blood count. The normal reference range is typically 80-100 fL.

Higher than Normal MCV

- In pernicious anemia (macrocytic), MCV can range up to 150 femtolitres.
- An elevated MCV is also associated with alcoholism (as are an elevated GGT and a ratio of AST:ALT of 2:1).
- Vitamin B12 and/or folic acid deficiency has also been associated with macrocytic anemia (high MCV numbers).

Lower than Normal MCV

- The most common causes of microcytic anemia are iron deficiency (due to inadequate dietary intake, gastrointestinal blood loss, or menstrual blood loss), thalassemia, sideroblastic anemia or chronic disease. In iron deficiency anemia (microcytic anemia), it can be as low as 60 to 70 femtolitres.
- In some cases of thalassemia, the MCV may be low even though the patient is not iron deficient (Tonnesen, 1986).

Mean corpuscular hemoglobin (MCH)

The mean corpuscular hemoglobin (MCH), or "mean cell hemoglobin" (MCH), is the average mass of hemoglobin per red blood cell in a sample of blood. It is reported as part of a standard complete blood count. MCH value is diminished in hypochromic anemias. It is calculated by dividing the total mass of hemoglobin by the number of red blood cells in a volume of blood. MCH= (Hgb*10)/RBC. A normal value in humans is 27 to 31picograms/cell.

Higher than Normal MCH

Generally, if the MCH level is over 34, this is considered to be too high. The main reason that the MCH level would be too high is because of macrocytic anemia.

- Macrocytic anemia is a blood disorder in which not enough red blood cells are produced, but the ones that are present are large (thus fitting more hemoglobin).
- Macrocytic anemia is often caused by having too little vitamin B12 or folic acid (a type of vitamin) in the body.

Lower than Normal MCV

Generally, if the MCH level is below 26, this is considered too low. The MCH level can be too low because of

- blood loss over time,
- too little iron in the body,
- or Microcytic anemia which is a condition in which abnormally small red blood cells are present. Smaller red blood cells means that less hemoglobin fits in each cell.
- Hemoglobinopathy, which is a group of disorders characterized by changes in the structure of hemoglobin, can also cause a low MCH level.

Mean corpuscular hemoglobin concentration (MCHC)

Mean corpuscular hemoglobin concentration (MCHC) is the average concentration of hemoglobin per unit volume of red blood cells and is calculated by dividing the hemoglobin by the hematocrit.

$MCHC = H_b / H_{ct} \times 100$

Normal range: 32-36 g/dL

When the MCHC is abnormally low they are called hypochromic, and when the MCHC is abnormally high, hyperchromic.

Red blood cell distribution width (RDW or RCDW)

Red blood cell distribution width (RDW or RCDW) is a measure of the variation of red blood cell (RBC) volume that is reported as part of a standard complete blood count. Usually red blood cells are a standard size of about 6-8 µm in diameter. Certain disorders, however, cause a significant variation in cell size. Higher RDW values indicate greater variation in size. Normal reference range in human red blood cells is 11.5-14.5%. If anemia is observed, RDW test results are often used together with mean corpuscular volume (MCV) results to determine the possible causes of the anemia. It is mainly used to differentiate an anemia of mixed causes from an anemia of a single cause.

Higher than Normal RDW

- Iron Deficiency Anemia: usually presents with high RDW with low MCV
- Folate and vitamin B12 deficiency anemia: usually presents with high RDW and high MCV
- Mixed Deficiency (Iron + B12 or folate) anemia: usually presents with high RDW with MCV being high, low or often normal range
- Recent Hemorrhage: typical presentation is high RDW with normal MCV
- A false high RDW reading can occur if EDTA anticoagulated blood is used instead of citrated blood.


1.5.4.2 White Blood Cell

White blood cells are different from red cells in the fact that they are usually larger in size 10-14 micrometers in diameter. White blood cells do not contain hemoglobin which in turn makes them translucent. Many times in diagrams or pictures white blood cells are represented in a blue color, mainly because blue is the color of the stain used to see the cells. White blood cells also have nucleii, that are some what segmented and are surrounded by electrons inside the membrane. White blood cells (leukocytes) are also known as "WBC's". White blood cells are made in the bone marrow but they also divide in the blood and lymphatic systems. They are commonly

amoeboid (cells that move or feed by means of temporary projections, called pseudopods (false feet), and escape the circulatory system through the capillary beds. Normal range of WBC: $3-7 \times 103$ mm3.

There are two types of WBC:

- ✓ Granular leukocytes: different types of granular WBC's are
- a. **Basophils**: Basophils store and synthesize histamine which is important in allergic reactions. They enter the tissues and become "mast cells" which help blood flow to injured tissues by the release of histamine.
- b. **Eosinophils**: Eosinophils are chemotoxic and kill parasites. Neutrophils are the first to act when there is an infection and are also the most abundant white blood cells.



Types of white blood cells

Figure-10: Different Parts of White Blood Cell and Platelet

c. Neutrophils: Neutrophils fight bacteria and viruses by phagocytosis which means they engulf pathogens that may cause infection. The life span of a Neutrophil is only about 12-48 hours.

Agranular leukocytes: Two types of agranular WBC are

a. **Monocytes**: Monocytes are the biggest of the white blood cells and are responsible for rallying the cells to defend the body. Monocytes carry out phagocytosis and are also called macrophages.

 b. B- and T-cell lymphocytes: Lymphocytes help with our immune response. There are two Lymphocytes: the B- and T- cell. B-Lymphocytes produce antibodies that find and mark pathogens for destruction. T-Lymphocytes kill anything that they deem abnormal to the body (Ganong, 2003).

1.5.4.3 Platelets

Platelets, also called thrombocytes, are membrane-bound cell fragments. Platelets have no nucleus, they are between one to two micrometers in diameter, and are about 1/10th to 1/20th as abundant as white blood cells. Less than 1% of whole blood consists of platelets. They result from fragmentation of large cells called Megakaryocytes - which are cells derived from stem cells in the bone marrow. Platelets are produced at a rate of 200 billion per day. Their production is regulated by the hormone called Thrombopoietin. The circulating life of a platelet is 8–10 days. The sticky surface of the platelets allow them to accumulate at the site of broken blood vessels to form a clot. This aids in the process of hemostasis ("blood stopping"). Platelets secrete factors that increase local platelet aggregation (e.g., Thromboxane A), enhance vasoconstriction (e.g., Serotonin), and promote blood coagulation (e.g., Thromboplastin). Normal range of platelet: 1000-1600×103mm3 (Ganong, 2003).

Functions:

Blood performs many important functions within the body including:

- Supply of oxygen to tissues (bound to hemoglobin, which is carried in red cells)
- Supply of nutrients such as glucose, amino acids, and fatty acids (dissolved in the blood or bound to plasma proteins(e.g., blood lipids)
- Removal of waste such as carbon dioxide, urea, and lactic acid
- Immunological functions, including circulation of white blood cells, and detection of foreign material by antibodies
- Coagulation, the response to a broken blood vessel, the conversion of blood from a liquid to a semi-solid gel to stop bleeding.
- Messenger functions, including the transport of hormones and the signaling of tissue damage
- Regulation of body pH
- Regulation of core body temperature

1.6 Hepatotoxicity

Hepatotoxicity The liver's status as the largest organ in the body reflects its key roles in many physiological processes, ensuring its undisputed position as 'metabolic coordinator' of the entire body. Due to the organ's importance to many body functions, any tendency for a chemical to damage the liver is taken very seriously in modern toxicology and risk assessment.

Several factors predispose the liver to xenobiotic toxicity:

- Firstly, for chemicals entering the body via the oral route, anatomical proximity to the GI-tract ensures the liver is the 'first port of call' for ingested xenobiotics.
- Secondly, chemicals and nutrients are not the only substances that enter portal blood as it perfuses the intestines: it also accumulates products of the degradation of intestinal microorganisms such as inflammogenic lipopolysaccharide components of the bacterial cell wall (i.e. endotoxin). Since endotoxin delivery may increase during xenobiotic intoxication, immunological responses to co-absorbed endotoxin can exacerbate the hepato-toxicity of ingested chemicals.
- Thirdly, in addition to entry via the portal circulation, chemicals can access the liver via arterial blood that mixes with venous blood in the hepatic sinusoids. For example, inhaled tobacco constituents that enter via the lungs are efficiently delivered to the liver via the arterial route.
- Fourthly, the vast metabolic capacities of the liver also paradoxically heighten its vulnerability to chemical toxicity: by functioning as a miniaturised chemical factory that performs many diverse chemical modifications on foreign molecules, CYPs and other hepatic enzymes can inadvertently generate noxious metabolites that induce 'bioactivation-dependent' hepatotoxicity (Philip and Burcham, 2014).

1.6.1 Liver

The liver is a vital organ of vertebrates and some other animals. In the human it is located in the upper right quadrant of the abdomen, below the diaphragm. The liver has a wide range of functions, including detoxification of various metabolites, protein synthesis, and the production of biochemicals necessary for digestion.




Figure-11: Anatomy of liver

The liver is a gland and plays a major role in metabolism with numerous functions in the human body, including regulation of glycogen storage, decomposition of red blood cells, protein synthesis, hormone production, and detoxification. It is an accessory digestive gland and produces bile, an alkaline compound which aids in digestion via the emulsification of lipids. The liver's highly specialized tissue consisting of mostly hepatocytes regulates a wide variety of highvolume biochemical reactions, including the synthesis and breakdown of small and complex molecules, many of which are necessary for normal vital functions (Maton et.al., 1993).

Function

- The liver is considered a gland—an organ that secretes chemicals—because it producesbile, a substance needed to digest fats. Bile's salts break up fat into smaller pieces so it can be absorbed more easily in the small intestine.
- Detoxifies the blood to rid it of harmful substances such as alcohol and drugs
- Stores some vitamins and iron

- Stores the simple sugar glucose
- Converts stored sugar to usable sugar when the body's sugar (glucose) levels fall below normal.
- Breaks down hemoglobin as well as insulin and other hormones
- Converts ammonia to urea, which is vital in metabolism
- Destroys old red blood cells

1.6.2 Liver function tests

Liver function tests (LFTs or LFs) are groups of blood tests that give information about the state of a patient's liver. These tests include prothrombin time (PT/INR), aPTT, albumin, bilirubin (direct and indirect), and others. Liver transaminases (AST or SGOT and ALT or SGPT) are useful biomarkers of liver injury in a patient with some degree of intact liver function (Mc.Clatchey, 2002). Several biochemical tests are useful in the evaluation and management of patients with hepatic dysfunction. These tests can be used to detect the presence of liver disease, distinguish among different types of liver disorders, gauge the extent of known liver damage, and follow the response to treatment (Johnston, 1999).

Use of liver function test

- Differential diagnosis of jaundice
- Diagnosis of liver damage
- ➤ To asses the extent of liver damage
- > To follow the progress of liver

Table-3: Reference value of different protein that distinguish the liver disorders

| Parameters | Reference value |
|---------------------|-----------------|
| Total Protein (g/L) | 60-80 |
| Albumin (g/L) | 33-45 |
| AST (U/L) | <35 |

| ALT (U/L) | <45 |
|--------------------------------|---------|
| ALP (U/L) | 54-128 |
| Total Bilirubin (µ mol/L) | 0.0-34 |
| Conjugated Bilirubin (µ mol/L) | 0.0-3.4 |

1.6.2.1 Albumin

Albumin is a protein made specifically by the liver, and can be measured cheaply and easily. It is the main constituent of total protein (the remaining from globulins). An alternative to albumin measurement is prealbumin, which is better at detecting acute changes (half-life of albumin and prealbumin is about 2 weeks and about 2 days, respectively). This test can help determine if a patient has liver disease or kidney disease, or if the body is not absorbing enough protein. Albumin helps move many small molecules through the blood, including bilirubin, calcium, progesterone, and medications. It plays an important role in keeping the fluid from the blood from leaking out into the tissues.

Decreased blood albumin levels may occur when your body does not get or absorb enough nutrients, such as:

- After weight-loss surgery
- Crohn's disease
- Low-protein diets
- Sprue
- Whipple's disease

Increased blood albumin level may be due to:

- Dehydration
- High protein diet
- Having a tourniquet on for a long time when giving a blood sample (Pratt, et.al. 2010).

1.6.2.2 Alkaline phosphatase

Alkaline phosphatase (ALP) is an enzyme in the cells lining the biliary ducts of the liver. The test may be done to diagnose liver or bone disease, to check, if treatments for those diseases are working and as part of a routine liver function test.

Higher-than-normal ALP levels

- Biliary obstruction
- Bone conditions
- Osteoblastic bone tumors, osteomalacia, a fracture that is healing
- Liver disease or hepatitis
- Eating a fatty meal if you have blood type O or B
- Hyperparathyroidism
- Leukemia
- Lymphoma
- Rickets

Lower-than-normal ALP levels

- Hypophosphatasia
- Malnutrition
- Protein deficiency
- Wilson's disease (Martin, 2011).

1.6.2.3 Aspartate transaminase

AST, also called serum glutamic oxaloacetic transaminase or aspartate aminotransferase, is similar to ALT in that it is another enzyme associated with liver parenchymal cells. The ratio of AST to ALT is sometimes useful in differentiating between causes of liver damage. This test is used to determine if a patient has liver damage (Nyblom et.al., 2004).

An increase in ALT levels may be due to:

- Cirrhosis (scarring of the liver)
- Death of liver tissue (liver necrosis)

- Hepatitis
- Lack of blood flow to the liver (liver ischemia)
- Liver tumor or cancer
- Medications that are toxic to the liver
- Pancreatitis (swollen and inflamed pancreas)

1.6.2.4 SGPT test This test measures the amount of an enzyme called glutamate pyruvate transaminase (GPT) in blood. This enzyme is found in many body tissues in small amounts, but it is very concentrated in the liver. It is released into the blood when cells that contain it are damaged. This enzyme is also called alanine transaminase, or ALT. The GPT level is tested to look for and evaluate damage to the liver. It is also measured to check medical treatments that may lead to liver inflammation.

SGPT levels may be higher than normal also if:

- drink too much alcohol
- chronic liver infection or inflammation
- gallbladder infection and inflammation, such as may caused by gallstones
- congested blood flow through the liver due to heart failure
- liver cancer or another cancer that has spread to the liver
- taking certain medicines, such as cholesterol lowering agent, antifungal medicines, some narcotics and barbiturates, methotrexate, acetaminophen, salicylates (aspirin). (Pratt, 2010).

Chapter 2 Introduction of Plant

2.1 Introduction of Plant, Mikania cordata

The plant, *Mikania cordata* (Bum.f) B.L. Robinson, is well known medicinal plant amongst traditional practitioner in India, Bangladesh, Brazil and Philiphines for its medicinal values that treat several local illness (Patar, AA. and Yahaya, 2012).



Figure-12: Whole Plant of *Mikania cordata*

2.1.1. Description of Mikania cordata:

2.1.1.1. Scientific name: Mikania cordata (Burm. F.) Robinson

2.1.1.2. Local Name:

- ✓ Indian Subcontinent: Assamlata, Germanlata and Taralata
- ✓ **English:** Heartleaf hempvine, Mile a minute.
- ✓ **Philippines**: Bikas.
- ✓ Chinese: jia ze lan
- ✓ **French:** liane marzoge, liane Pauline, liane raisin

2.1.1.3. Taxonomic position

Kingdom: Plantae Division: Magnoliophyta Class: Magnoliopsida, Order: Asterales Family: Asteraceae Genus: Mikania Species: Mikania cordata

2.1.1.4. Description

A fast growing, creeping or twining, perennial vine; stems branched, pubescent to glabrous, ribbed, from 3 to 6 m long; leaves opposite, cordate or triangular-ovate, blade 3 to 12 cm long, 2 to 6 cm wide, on a slender petiole 1 to 8 cm long, base broadly cordate, tip acuminate, margins crenate, dentate, or entire, surfaces nearly glabrous, three- to seven-veined from base; flowers in small heads in open, nearly flat-topped (corymbose) panicles; axillary and terminal heads 6 to 9 mm long, four-flowered; involucral bracts four, obtuse or acute, 5 to 6 mm long, glabrous or subglabrous with one additional smaller bract about 3 mm long; corolla white or yellowish white, about 5 mm long; anthers bluish gray or grayish black; style white; fruit an achene, linear-oblong, 2 to 3 mm long, five angled, blackish brown, glandular; pappus of 40 to 45 bristles, about 4 mm long, white at first, reddish afterwards. May be distinguished by the following characteristics: 40 to 45 reddish pappus bristles, corollas white, and heads 7 to 7.5 mm long (Holm *et. al.*, 1977).

2.1.2. Habitat/ecology

Grows most frequently in places receiving high rainfall, probably 1,500 mm or more; prefers rich, damp soil; rarely grows in dry areas; and thrives in open, disturbed places. For that reason it is common in young secondary forests, in forest clearings, in plantation tree crops, fallow or neglected lands, and along rivers and streams, waste areas, steep hillsides, and even mountainsides from whence winds probably spread the seeds to new areas. The species will grow in partial shade, but cannot tolerate dense shade" (Holm et al., 1977).

2.1.3. Geographical Distribution

Mikania (Asteraceae) species are found throughout tropical regions of Africa, Asia (Bangladesh, India), Brazil and South America (Argentina, Paraguay and Uruguay) *Mikania* is native to Central and South America, and has become a serious weed in West Africa through to India, South-East Asia, Indonesia and the Pacific Islands. *Mikania* was first found in Australia in 1998 at Ingham and Bingil Bay, and has since been detected at one location near Speewah, near Mareeba (Chowdhury et.al., 2011).

2.1.4. Chemical composition

Different classes of compounds were previously isolated from various *Mikania* parts, which can be associated to this plant's pharmacological activities. The main groups are: coumarins and derivatives, sesquiterpenes, sesquiterpenes lactones, diterpenes, phytosterols/terpenoids and flavonoids. Caffeoylquinic acid derivatives beyond others chemical compounds are found in smaller amount. Diterpenes such as kaurenoic acid and benzoylgrandifloric acid (class of kauranes), have also attracted interest for their pharmacological action. Moreover, detailed screenings revealed the presence of other substances in species of *Mikania* as alcohols, acids, esters, aldehydes and organic esters (Gasparetto et. al., 2010).

Coumarins and derivatives

The most characteristic class of compounds in *Mikania* genus is the coumarins and derivatives, frequently responsible for pharmacological activity. A wide variety of biological activities is assigned for these compounds, such as antimicrobial, antiviral, anti-inflammatory, antispasmodic, antitumoral, anticoagulant, bronchodilator and antioxidant (Pereira et al., 1994; Hoult & Payá, 1996). The coumarin (1,2-benzopyran), dihydrocoumarin and o-coumaric acid scopoletin, O-geranylscopoletin herniarin (7-methoxycoumarin) and 2,6-dimethoxyquinone were identified in extracts of Mikania genus (Vidal et al., 2006).

Sesquiterpenes and terpenes, diterpenes and sesquiterpenes lactones

Sesquiterpenes are abundant in Mikania genus, related to that the most commom are germacrene D, isocomene and γ -humulene. These compounds were reported in around 15% of Mikania species that already had their chemical composition determined, (Bohlmann et al., 1982). Likewise, terpenes, diterpenes and sesquiterpene lactones are often found, mainly the lactones type mikanolide and miscandenin derivatives, which have analgesic activity (Ahmed et al., 2001), antibacterial (Facey et al., 2010) and anticancer properties (Prevost et al., 2002).

| Plant specie | Geographic Distribution | Part used | Compounds | Structure |
|--------------|----------------------------|-------------|---|-------------|
| M. cordata | Asia | Leaves | α-cubebene (21.3%), caryophyllene oxide (10.1%), α-bisabolol (6.6%), γ-curcumene (6.3%), β-pinene (4.1%), copaene (4.1%), α-cedrene (4.9%), spathulenol (3%) | α-cubebene |
| M. cordata | Asia | flowers oil | β-pinene (14.9%), α-cubebene (12.4%), γ-curcumene (11.7%) aryophyllene (8.5%), α-bergamotene (5.6%), β-caryophyllene(4.3%), zingiberene (6%) | γ-curcumene |

Table-: Different isolated compound in different parts of Mikania Cordata

> Diterpenes

Some diterpenes are common in *Mikania* genus like kaurenoic acid, which is characterized by its trypanocidal activity. Also, the kaurenoic acid has other important activities such as antimicrobial, antinociceptive, anti-inflammatory and smooth muscle relaxant. In a study performed by on leaves of *Mikania* sp. nov., found in the state of Bahia, Brazil, several diterpenes were obtained: labda-8(17),12,14-trien-19-oic methyl ester, pimara-9(11),15-dien-19-oic methyl ester, labda-8(17),13(16),14-trien-19-oic methyl ester, labda- 12 α -epoxy-8(17),14-dien-19-oic methyl ester, erythroxyla-3,15-dien-19-oic acid, labda-12,15- epoxy-8(17),13-dien-19-oic acid, and labda-12,13-dihydroxy-8(17),14-dien-19-oic methyl ester (Gasparetto et. al., 2012).

> Phytosterols/terpenoids

The most common phytosterols present in approximately 10% of species of *Mikania*, that has its chemical composition determined, are stigmasterol, lupeol and sitosterol. These compounds have been detected in the aerial parts and are found in the species *M. cordata* (Aguinaldo et. al.,2003). The terpenoids amyrin and friedelin , abundant in *Mikania* genus, were reported in *M. micrantha*, *M. cordata*, *M. cordifolia* (Oliveira et. al., 2006).

> Flavonoids

Flavonoids are popular due to their antioxidant activity and are widely present in *Mikania* genus supporting its pharmacological activity. In *M. cordata*, flavonoids were described as patuletine-3-*O*- β -D-6"-(p-coumaroyl),glucoside(6-methoxyquercetin-3-*O*- β -D-6"-(*p*coumaroyl) glucoside), mikanin-3-*O*-sulfate (salt as Ca+2), eupalitin-3-*O*-sulphate (as salt K+), eupalitin- 3-*O*- β -D-glucoside, 6-methoxykaempherol-3-*O*- β - D-glucoside, nepetin and kaempherol-3-*O*- α -Lrhamnoside. For the same species, it was reported the isolation of a flavone, mikanin-(3,5dihydroxy-4',6,7-trimethoxyflavone) with epifriedelinol from roots and fumaric acid from leaves and stems (Aguinaldo et. al., 2003).

Caffeoylquinic acid and derivatives

The chemical compound 5-caffeoylquinic acid is a caffeic acid ester, also known as a chlorogenic acid, commonly found in a wide number of plants, *e.g.* coffee. It is produced in plants via an ester bond between the carboxyl group of caffeic acid and the 5-hydroxyl group of quinic acid (Clifford et al., 2006). The chlorogenic acid and caffeic acid were reported as dampening the risk of chronic diseases such as inflammation, cardiovascular diseases and cancer (Boyer & Liu, 2004; Bonita et. al., 2007).

2.1.5. Pharmacological activities

The *Mikania* species have multiple pharmacological actions. In general, activity in respiratory tract, anti-inflammatory, anti-allergic, analgesic, antioxidant even in system nervous central. In this section, our aim is to highlight the pharmacological experiments and studies reported with species of the genus *Mikania*.

> Activity in the respiratory tract

Medicinal plants play an important role in maintaining public health, mainly due to their low cost and availability. Some plants acting in the respiratory system, such as *Mikania* genus, have confirmed their effectiveness. For example, *M. glomerata*, one of the most important and commonly used species *Mikania* genus, has been popularly used in the treatment of asthma, bronchitis and coughing (Agra et.al., 2008). Other species, known as "guaco" are also used to treat respiratory problems as *M. cordifolia* (Oliveira et.al., 2006), *M. laevigata*, and *M. cordata* (Ali et.al., 2011).

Activity in the digestive system

Many plants and their extracts are commonly used for acting against several disorders of the digestive system. Among them are some species of the genus *Mikania* as *M. glomerata*, *M. laevigata* and *M. cordata*. Moreover, the decoction of the leaves of *M. cordata* also shows effects in the digestive system. It is used in dyspepsia, dysentery and gastric ulcer (Ghani, 1998). The methanolic fraction of root extract showed antiulcer effects in male Sprague-Dawley rats in

a dose dependently manner inhibiting gastric ulcers induced by water immersion stress-induced, ethanol, aspirin and phenylbutazone.

Effect on nervous system

Mikania extracts possesses some neuropharmacological properties confirmed. The studies with methanolic fraction of *M. cordata* root extract on experimental animals caused alterations in the general behavior pattern (*e.g.* reduction in spontaneous motility, analgesia, and suppression of aggressive behaviour), suppression of conditioned avoidance response and showed antagonism to amphetamine toxicity. The observations suggest that the root of *M. cordata* possesses a potent central nervous system depressant action (Bhattacharya et. al., 1988).

Anti-inflammatory, anti-allergic and analgesic activity

The inflammatory response is associated with a range of diseases and it is difficult to establish an effective therapy to control the inflammatory processes. So, there is a clear and obvious need to search for new medicinal compounds, especially those derived from plants. Studies with extracts, oils and compounds of several species have demonstrated their important activity. The compound scandenolide, a sesquiterpene lactone present in *M. cordata*, exhibited anti-inflammatory activity. It also inhibited the production of leukotriene B4 and 5-HETE with IC50 of 15 and 30 μ M concentration, respectively (Ysrael & Croft, 1990). In addition, the crude extract of *M. cordata* (1 and 3 g/kg) and a sesquiterpene lactone deoxymikanolide (10 mg/kg) significantly inhibited acetic-acid induced writhing in mice (Ahmaed et. al., 2001).

> Antimicrobial, antivirucidal and antiparasitic activity

The antimicrobial and antiparasitic properties of compounds present in plants as products of secondary metabolism have been known empirically for centuries, but only recently they have been scientifically confirmed. Extracts and essential oils from plants proved their efficacy in controlling the growth of a wide variety of microorganisms, including bacteria, fungi, parasites and others. In a study carried out with hexanic extract of *M. cordata*, it was observed the inhibition growth of a multiresistant strain of *Staphylococcus aureus* PI57, verified by antibiogram and bioautography.

> Antiophidic activity

Although serotherapy was discovered one hundred years ago, many rural communities do not have access to antivenoms. In this way, they alternatively use plants with antiophidic activity known in popular culture, such as some species of the genus *Mikania*. The extract components were effective in mammals to inhibit the letal effects of poisonous animals, such as nauyaque snake and rattlesnake, scorpions, spiders and bees. The author has indicated its use for treating snake bites, scorpion stinging, bee sting and similar.

Antimutagenic and cytotoxic activity

The natural products provide very important chemical libraries that have led to new antimutagenic drugs (Cragg et.al., 2009). The chemopreventive role of *M. cordata*, was evaluated for its effects on phase 1 and 2 of the hepatic drug detoxifying enzyme system in rats (Bishayee & Chatterjee, 1994). In oral doses of 50, 100, or 150 mg/kg of extract for 4, 8 or 12 weeks results in dose dependent effects on a marked induction of uridine diphosphoglucuronyl transferase activities of liver microsomes and others effects. The study indicated that the carcinogens would be reduced by specific enhancement of drug-detoxifying enzymes in the liver of rats treated with the plant extract.

> Allelopathic activity

Allelopathy is defined as any indirect or direct, beneficial or damaging effect, from a plant to other, resulted from the production of chemical products which are released into the environment. The same chemical compounds responsible for the allelopathic activity can be modulated in some pharmacological activity. It has also attracted great interest due to their potential applications in agriculture and therefore has been studied in several plants.

Chapter 3 Material & Method

3.1 Plant Preparation

3.1 Plant Preparation

3.1.1 Collection of plant

The plant was collected from Foridpur district of Bangladesh. A voucher specimen (Accession number: 38479) had been deposited at the Bangladesh National Herbarium. The proper time of harvesting or collecting is particularly important because the nature and the quantity of constituents very gently in some species according to the season.




Figure-14: Herbarium sheet of Mikania cordata

3.1.2 Preparation of plant extraction

The whole part of the plant was dried in room temperature for approximately two weeks. Then the dried plants were taken into fine powder by using a grinding machine. Then the extraction process was done.

At first 2kg dried plant dust of *Mikania cordata* was soaked in L methanol in four bottles. Then it was kept in room temperature for 3 days and everyday it was used to shake properly to ensure the maximum amount of constituents present in the grinded plant become soluble into methanol. After 3 days later, the mixture was filtered. For filtration, white cotton cloth was used. After filtration two parts were obtained.

1. The residue portion over the filter

2. The filtered part

The filtrated part, which contains the substance soluble in methanol, poured into a 1000 round bottle flask, and then the flask was placed in a rotary evaporator. The evaporation was done at 53 degree Celsius temperature. The number of rotation per minute was selected as 125 RPM. The pressure of vacuum pump machine was 6 bars. The water flow through the distillation chamber was also provided in a satisfactory flow rate.





Figure-15: Rotary evaporator & crude extract in a bottle

3.2 Experimental Animals

Swiss mice of either sex (25-35 g) were obtained from the Animal house of the International Centre for Diarrhoeal Disease and Research, Bangladesh (ICDDR, B). The animals were housed under standard laboratory conditions (relative humidity 55-65%, r.t. 23.0±2.0°C and 12 h light: dark cycle). The animals were fed with standard diet and water ad libitum.





Figure-18: Swiss albino Mice

3.3. CNS Activity Test

3.3.1. Materials for CNS Activity Test:

- Analytical Balance,
- Feeding needle: 1 c.c.
- Insulin syringes 100 units both disposable and nondisposable
- Open Field Board
- Hole board
- Lamp light
- Stop Watch

3.3.2. Chemical Agents Used in Analgesic activity Test:

• 5% CMC (Vehicle) 10ml/kg as negative control,

3.3.3. Standard Drugs Used in CNS activity Test:

- Diazepam 1mg/kg used as positive control in open field test.
- Diazepam 1mg/kg used as positive control in hole board test.

3.3.4. Doses Used in CNS Activity Test of the Extract:

i) Open Field Test:

• Methanolic extracts of *Mikania cordata* at a dose of 200mg/kg and 400mg/kg of the crude extract are administered orally. 5% CMC was used as a vehicle with plant methanolic extract for preparing different doses.

ii) Hole Board Test:

• Methanolic extracts of *Mikania cordata* at a dose of 200mg/kg and 400mg/kg of the crude extract are administered orally. 5% CMC was used as a vehicle with plant methanolic extract for preparing different doses.

3.3.5. Methods for CNS Activity Test:

To determine CNS effect of the plant extract two different methods are used with different groups of testing animals. These methods are-

- Open Field Test.
- Hole Board Test.

After the extraction of the plant, each group is treated with the extract in order to determine some specific parameters according to the experimental protocol.

Open Field Test:

In this experiment, the method according to Gupta, 1971 was employed. An open field, a test paradigm which is highly standardized to evaluate locomotor activity (Kelley, 1993). The animals were divided into negative control, positive control and test groups containing six mice in each group. Negative control group received vehicle (5% CMC solution) at a dose of 10 mg/kg body weight orally. The test groups received extracts of *Mikania cordata* at the doses of 200 and 400 mg/kg body weight orally. The floor of an open field of half square meter was divided in to a series of squares, each alternatively colored black and white. It has 49 squares. The number of Peripheral locomotion (movement of mice on surrounding 40 squares other than central 9 squares), number of Central locomotion (movement of mice on central 9 squares), number of Leaning (standing of mice with the help of wall) and number of Rearing (standing of mice without any help) number of Grooming (face rubbing or itching), and number of defecation was recorded for a period of two minutes. The observation was conducted at 0, 30, 60, 90 and 120 minutes after oral administration of test drugs and was compared with control animal.





Figure-19: Open Field Test

Hole Board Test

The hole board represents a combination of a hole board, originally designed to investigate explorative motivation in rodents and later on modified to evaluate cognitive functions (Ohl and Fuchs, 1999; Ohl et al., 1998) The hole board itself consisted of a total of 16 holes, each 3 cm in diameter, were presented to the mouse in a flat space of 25 square centimeters. This experiment was carried out by the following method of Boisser and Simon, (1964). The animals were

divided into negative control and test groups containing six mice in each group. Negative control group received vehicle (5% CMC solution) at a dose of 10 mg/kg body weight orally. The test groups received extracts *Mikania cordata* at the doses of 200 and 400mg/kg body weight orally. Each of the animal was transferred carefully to one corner of the field and the number of ambulation (expressed as the number of holes passed), head dipping and number of head poking was recorded for a period of 5 minutes at and post 30 minutes intervals and were compared with the control animals.






Figure-20: Hole Board Test

3.5 Toxicity Test

3.5.1 Materials for Toxicity Test

- Analytical Balance,
- Feeding needle: 1 c.c.
- Insulin syringes 100 units disposable
- 5 ml syringe disposable
- Dissecting box
- Dissecting pad
- Pin
- Beaker 1 litre
- Petri dish for washing
- Epindrop tube
- 250 ml food grade plastic pot

- Gloves
- Mask

3.5.2 Chemical Agents Used Toxicity Test

- 5% CMC (Vehicle) 10ml/kg as negative control,
- Saline water (0.9%)
- Formalin (5%)
- EDTA
- Heparin

3.5.3 Doses Used for Toxicological Activity of the Extract:

i) Acute Toxicity Test:

Methanolic extracts of *Mikania cordata* at a dose of 2000mg/kg, 3000mg/kg and 6000mg/kg were administered orally. 5% CMC was used as a vehicle with plant methanolic extract for preparing different doses.

ii) Chronic Toxicity Test:

Methanolic extracts of *Mikania cordata* at a dose of 200mg/kg and 400 mg/kg and are administered orally. 5% CMC is used as a vehicle with plant methanolic extract for preparing different doses.

3.5.5. Hematological parameters

Collected blood was used for the estimation of hemoglobin (Hb) content; red blood cell count (RBC) and white blood cell count (WBC).

3.5.6. Serum biochemical parameters

Collected blood was used for the estimation of serum biochemical parameters like serum glutamate oxaloacetate transaminase (SGOT), serum glutamate pyruvate transaminase (SGPT), serum alkaline phosphatase (SALP), serum total cholesterol, total protein, urea, uric acid and creatinine contents by using commercially available reagent kits.

3.5.7. Histopathological studies

After sacrifice the organs like heart, lung, liver, kidney and pancreas of animals from each group were subjected for histopathological examinations. After fixing the tissues in 10% formaldehyde the tissues were dehydrated and paraffin blocks were made. Then sectioning was done at about 5-7µ. Routine histopathology was performed by using the Haemotoxylin stain (Paul, et.al., 2012).

3.6. Statistical Analysis

Data obtained from pharmacological experiments are expressed as mean±SEM. Difference between the control and the treatments in these experiments were tested for significance using one-way analysis of variance (ANOVA), followed by Dunnet's t-test for multiple comparisons using SPSS -16 software.

4.1 4 CNS Activity Test of Methanolic Extract of Mikania cordata

4.1.1. Open Field Test:

The test is carried out to determine whether the extract of *Mikania cordata* has any locomotor activity or not. The experimental findings that are noted are below-

<u>Total Number of Peripheral locomotion, Central locomotion, Leaning, Rearing,</u> <u>Grooming, Defecation count</u>

Negative Control Group (5% CMC, 10 ml/kg)

This group of animals only received vehicle (5% CMC) 10 ml/kg orally.

- ✓ The observed total number of peripheral locomotion count is followed with a mean value of at 0 min 121.50±1.05, at 30 min 121±2.62, at 60 min 118±0.56, at 90 min119.83±0.79 and at 120 min 121.83±1.10 (Mean ±SEM) during 2 minutes observation.
- ✓ The observed total number of central locomotion count is followed with a mean value of at 0 min 22.67±1.22, at 30 min 20.67±0.91, at 60 min 21.50±0.92, at 90 min 21.0±0.57 and at 120 min 121.83±1.10 (Mean ±SEM) during 2 minutes observation.

Chapter 4 Results and Discussion

- ✓ The observed total number of leaning count is followed with a mean value of at 0 min 20.33±0.76, at 30 min 21.16±2.13, at 60 min 21.33±0.80, at 90 min 17.67±0.76 and at 120 min 21.33±0.80 (Mean ±SEM) during 2 minutes observation.
- ✓ The observed total number of rearing count is followed with a mean value of at 0 min 0.67±0.33, at 30 min 0.67±0.33 ,at 60 min 0.16±0.16, at 90 min 0.67±0.21 and at 120 min 1.00±0, 25 (Mean ±SEM) during 2 minutes observation.
- ✓ The observed total number of grooming count is followed with a mean value of at 0 min 0.50±0.22, at 30 min 0.50±0.22, at 60 min 0.50±0.34, at 90 min 0.67±0.21 and at 120 min 0.66±0.21 (Mean ±SEM) during 2 minutes observation.
- ✓ The observed total number of defecation count is followed with a mean value of at 0 min 0.67±0.21, at 30 min 0.67±0.21, at 60 min 0.50±0.22, at 90 min 0.83±0.30 and at 120 min 0 (Mean ±SEM) during 2 minutes observation.

Test Group-1 (Plant Extract, 200mg/kg)

This test group of mice receive the plant extract of 200 mg/kg orally.

- ✓ The observed total number of peripheral locomotion count is followed with a mean value of at 0 min 67.83±1.42, at 30 min 43.67±1.61, at 60 min 41.0±1.13, at 90 min 38.33.±1.98 and at 120 min 23.17±1.14 (Mean ±SEM) during 2 minutes observation.
- ✓ The observed total number of central locomotion count is followed with a mean value of at 0 min 17.5±.76, at 30 min 8.5±0.76, at 60 min 4.83±0.48, at 90 min 2.16±1.67 and at 120 min 2.16.±1.67 (Mean ±SEM) during 2 minutes observation.
- ✓ The observed total number of leaning count is followed with a mean value of at 0 min 10.17±0.60, at 30 min 7.5±0.42, at 60 min 6.5±0.42, at 90 min 4.5.±0.43 and at 120 min 1.33±0.2 (Mean ±SEM) during 2 minutes observation.
- ✓ The observed total number of rearing count is followed with a mean value of at 0 min 0.83±0.83, at 30 min 1.67±1.05, at 60 min 2.00±1.12, at 90 min 1.0±1.0 and at 120 min 0 (Mean ±SEM) during 2 minutes observation.

- ✓ The observed total number of grooming count is followed with a mean value of at 0 min 3.0±0.73, at 30 min 1.67±0.76, at 60 min 0.33±0.33, at 90 min 0.83±0.54 and at 120 min 0(Mean ±SEM) during 2 minutes observation.
- ✓ The observed total number of defecation count is followed with a mean value of at 0 min 0.33±0.21, at 30 min 0, at 60 min 0, at 90 min 0.16±0.16 and at 120 min 0 (Mean ±SEM) during 2 minutes observation.

Test Group-2 (Plant Extract, 400mg/kg)

These groups of mice receive the plant extract of 400 mg/kg orally.

- ✓ The observed total number of peripheral locomotion count is followed with a mean value of at 0 min 53.83±1.49, at 30 min 32.71±1.66, at 60 min 31.0±1.81, at 90 min 28.0±1.82 and at 120 min 22.50±.76 (Mean ±SEM) during 2 minutes observation.
- ✓ The observed total number of central locomotion count is followed with a mean value of at 0 min 13.5±1.87, at 30 min 3.5±0.43, at 60 min 3.0±0.36, at 90 min 2.3±0.21 and at 120 min 2.10±1.7 (Mean ±SEM) during 2 minutes observation.
- ✓ The observed total number of leaning count is followed with a mean value of at 0 min 7.33±0.49, at 30 min 5.67.0±0.49, at 60 min 4.33±0.49, at 90 min 2.5±0.42 and at 120 min 1.5±0.30 (Mean ±SEM) during 2 minutes observation.
- ✓ The observed total number of rearing count is followed with a mean value of at 0 min 0, at 30 min 0, at 60 min 0.83±0.54, at 90 min 0 and at 120 min 0.50±0.50 (Mean ±SEM) during 2 minutes observation.
- ✓ The observed total number of grooming count is followed with a mean value of at 0 min 1.83±0.60, at 30 min 0.33±0.33, at 60 min 0 at 90 min 1.16±0.74 and at 120 min 0(Mean ±SEM) during 2 minutes observation.
- ✓ The observed total number of defecation count is followed with a mean value of at 0 min 0.50±0.22, at 30 min 0.33±0.21, at 60 min 0.16±0.16, at 90 min 0 and at 120 min 0 (Mean ±SEM) during 2 minutes observation.


Positive Control Group (Diazepam, 1mg/kg)


This group of mice receives the standard drug Indomethacin of 10mg/kg orally.

- ✓ The observed total number of peripheral locomotion count is followed with a mean value of at 0 min 111.67±1.3, at 30 min 69.0±1.06, at 60 min 50.0±1.54, at 90 min 26.83±1.19 and at 120 min 15.0±1.41 (Mean ±SEM) during 2 minutes observation.
- ✓ The observed total number of central locomotion count is followed with a mean value of at 0 min 19.16±1.01, at 30 min 9.83±0.79, at 60 min 4.16±0.47, at 90 min 3.00±0.51 and at 120 min 2.0±0.25 (Mean ±SEM) during 2 minutes observation.
- ✓ The observed total number of leaning count is followed with a mean value of at 0 min 18.33±0.42, at 30 min 9.0±0.57, at 60 min 7.5±0.42, at 90 min 5.0±0.36 and at 120 min 2.83±0.54 (Mean ±SEM) during 2 minutes observation.
- ✓ The observed total number of rearing count is followed with a mean value of at 0 min1.0±0.36, at 30 min 0, at 60 min 0, at 90 min 0 and at 120 min 0 (Mean ±SEM) during 2 minutes observation.
- ✓ The observed total number of grooming count is followed with a mean value of at 0 min 1.0±0.25 at 30 min 0, at 60 min 0, at 90 min 0 and at 120 min 0 (Mean ±SEM) during 2 minutes observation.
- ✓ The observed total number of defecation count is followed with a mean value of at 0 min 0.83±0.30, at 30 min 1.0±0.36, at 60 min 1.16±0.30, at 90 min 0.33±0.21 and at 120 min 0.50±0.22 (Mean ±SEM) during 2 minutes observation.

| CNS Activity of plant extract of Mikania cordata by Open Field Test (Central |
|--|
| Locomotion) in Mice. |

| Groups | Dose | No. of Central Locomotion | | | | |
|--|----------|---------------------------|------------|------------|------------|------------|
| | | 0 min | 30 min | 60 min | 90 min | 120 min |
| Negative control 5% CMC | 10ml/kg | 20.0± 1.32 | 11.33±1.32 | 14.5± 1.98 | 12.3 ±1.52 | 13.5± 1.43 |
| Crude extract of <i>Mikania</i> <i>cordata</i> | 200mg/kg | 17.5±.76 | 8.5±.76 | 4.83±0.48 | 2.67±0.33 | 2.16±1.67 |
| Crude extract of <i>Mikania</i> <i>cordata</i> | 400mg/kg | 13.5±1.87 | 3.5±0.43 | 3.0±0.36 | 2.3±0.21 | 2.10±1.7 |
| Positive control, Diazepam | 1mg/kg | 20.67±1.05 | 9.5±0.76 | 6.17±0.6 | 4.17±0.6 | 3.33±0.42 |





| Groups | Dose | No. of Peripheral Locomotion | | | | | |
|--|--------------|------------------------------|------------|------------|------------|------------|--|
| | | 0 min | 30 min | 60 min | 90 min | 120 min | |
| Negative control 5% CMC | 10ml/kg | 109.33±3.3 | 107.67±2.7 | 76.83±3.58 | 88.83±1.89 | 88.17±3.39 | |
| Crude extract of <i>Mikania</i> <i>cordata</i> | 200mg/k g | 67.83±1.42 | 43.67±1.61 | 41.0±1.13 | 38.33±1.98 | 23.17±1.14 | |
| Crude extract of <i>Mikania</i> <i>cordata</i> | 400mg/k g | 53.83±1.49 | 32.71±1.66 | 31±1.81 | 28±1.82 | 22.50±.76 | |
| Positive control, Diazepam | 1mg/kg | 121.83±1.1 | 69.33±1.12 | 53.0±1.81 | 35.67±1.17 | 27.83±1.72 | |

CNS Activity of plant extract of *Mikania cordata* by Open Field Test (Peripheral Locomotion) in Mice.




Fig: No. of Peripheral Locomotion

| Groups | Dose | No. of Leaning | | | | |
|--|--------------|----------------|---------------|-----------|-----------|-----------|
| | | 0 min | 30 min | 60 min | 90 min | 120 min |
| Negative control 5% CMC | 10ml/kg | 16.67±1.54 | 13.5±0.76 | 9±0.73 | 10±0.58 | 12.83±1.4 |
| Crude extract of <i>Mikania</i> <i>cordata</i> | 200mg/ kg | 10.17±.60 | 7.5±.42 | 6.5±.43 | 4.5±.43 | 1.33.±.21 |
| Crude extract of <i>Mikania</i> <i>cordata</i> | 400mg/ kg | 7.33±.49 | 5.67±.49 | 4.33±.49 | 2.5±.42 | 1.23±.30 |
| Positive control, Diazepam | 1mg/kg | 22.17±1.08 | 8.83±0.31 | 6.17±0.31 | 4.33±0.33 | 3.17±0.48 |

CNS Activity of plant extract of *Mikania cordata* by Open Field Test (Leaning) in Mice.




Fig: No. of Leaning

1.1.2. Hole Board Test:

The test is carried out to determine whether the extract of *Mikania cordata* has any cognitive activity or not. The experimental findings that are noted are below-

Total Number of Head Poking and Head Dipping count

Negative Control Group (5% CMC, 10 ml/kg)

This group of animals only received vehicle (5% CMC) 10 ml/kg orally. The observed total number of head poking is with a mean value of 54.33 ± 0.88 (Mean ±SEM) and head dipping with mean value of (Mean ±SEM) during 5 minutes observation after 30 min of administration.

Test Group-1 (Plant Extract, 200mg/kg)

This test group of mice receive the plant extract of 200 mg/kg orally. The observed total number of head poking is with a mean value of 32.67 ± 0.88 (Mean ±SEM) and head dipping with mean value of 29.17 ± 1.17 (Mean ±SEM) during 5 minutes observation after 30 min of administration.

Test Group-2 (Plant Extract, 400mg/kg)


This group of mice receive the plant extract of 400 mg/kg orally. The observed total number of head poking is with a mean value of 23.83 ± 1.11 (Mean ±SEM) and head dipping with mean value of $33.67\pm.56$ (Mean ±SEM) during 5 minutes observation after 30 min of administration.

Positive Control Group (Indomethacin, 10mg/kg)

This group of mice receives the standard drug Diazepam of 1 mg/kg orally. The observed total number of head poking is with a mean value of 54.33 ± 0.88 (Mean \pm SEM) and head dipping with mean value of (Mean \pm SEM) during 5 minutes observation after 30 min of administration.

| Groups | Treatment | Dose | No. of Head | No. of Head |
|------------------|-------------------------------------|----------|-------------|-------------|
| | | | Poking | Dipping |
| Negative control | 5% CMC | 10ml/kg | 68.5±1.48 | 25.17±1.01 |
| Group-1 | Crude extract of Mikania cordata | 200mg/kg | 23.83±1.11 | 33.67±.56 |
| Group-2 | Crude extract of Mikania cordata | 400mg/kg | 29.17±1.17 | 32.67±1.20 |
| Positive control | Diazepam | 1mg/kg | 29.83±1.01 | 15.67±0.67 |

CNS Activity of plant extract of Mikania cordata by Hole Board Test in Mice.





4.4.2.1. CBC (Count Blood Cell) Test, Biochemical Test & Histological Studies

Drug dose 200,400 mg/kg (CBC & Biochemical Test):

In the subchronic study of methanolic extract of *Mikania cordata* at a dose (200,400 mg/kg) to the mice, significant difference were found in the erythrocyte and leucocytes values of both the treated and control mice. In which case, the administration of *Mikania cordata* methanol extract for a period of 90 days induce significant anaemia. Also some irregularities were observed mainly in the RBC, WBC, Platelet and SGPT (hepatic enzymatic test). This could be as a result of the mice response to foreign bodies associated with the chronic toxicity during the experiment. In sub-chronic study, we observed significant decrease in body weights than

Mikania cordata treated group (after 90 days) from control group. The toxicity assay also result some abnormality and mortality of the tested mice for the period of 90 days monitored. At the end of the study (after 90 days) and overall 12 mice died in 2 doses of groups.

Effect of mikania cordata on the count of WBC (white Blood cell)

| Treatment Group | Total WBC 10 ^{3/} mm ³ | Neutrophil | Lymphocyte | Monocyte | Eosinophil | Basophil |
|--------------------------------------|---|------------|------------|----------|------------|----------|
| Negative control (Female) | 3.9 | 19.72 | 76.0 | 72.9 | 0.68 | 0.75 |
| Negative control (Male) | 5.43 | 18.32 | 76.18 | 4.15 | 0.67 | 0.68 |
| Mikania cordata, 400mg/kg,Male | 13.28 | 22.32 | 362 | 3.6 | 0.52 | 0.78 |
| Mikania cordata, 200mg/kg, Female | 10.28 | 23.15 | 71.7 | 4.1 | 68 | 0.93 |




Fig: Effect of *mikania cordata* on the count of WBC (white Blood cell)

| Treatment Group | Total RBC 10 ^{6/} mm ³ (n) | Haemoglobin | НСТ | MCV | МСН | MCHC | RDW |
|---|--|-------------|-------|-------|-------|-------|-------|
| Negative control group (Female) | 8.33 | 14.5 | 55.5 | 64.25 | 25.9 | 25.9 | 21.58 |
| Negative control group (Male) | 8.79 | 13.55 | 50.3 | 56.7 | 15.28 | 26.93 | 22.28 |
| Mikania cordata (200mg/kg, Female) | 8.67 | 9.48 | 43.04 | 49.98 | 14.1 | 28.38 | 22.56 |
| Mikania cordata (400/ kg, Male) | 8.54 | 13.22 | 40.62 | 47.46 | 15.52 | 32.66 | 24.68 |

Effect of Mikania cordata on the count of RBC (Red Blood cell)




Fig : Effect of Mikania cordata on the count of RBC (Red Blood cell)

| Treatment Group | Pltelet 103/mm ³ (n) |
|-------------------------------------|------------------------------------|
| Negative Control group (Female) | 848 |
| Negative Control group (Male) | 1221 |
| Mikania cordata (200mg/kg , Female) | 1227.25 |
| Mikania cordata (400/ kg, Male) | 1360.2 |

Effect of Mikania Cordata on platelet count on the CBC (Count Blood Cell)




Fig :Effect of Mikania Cordata on platelet count on the CBC (Count Blood Cell)

| Treatment Group | SGPT (IU/dI) | SGOT (IU/dl) | SALP (IU/dl) |
|--|--------------|--------------|--------------|
| Negative control group(Female) | 55.83 | 33.33 | 102.17 |
| Negative contrl group (Male) | 49.17 | 31.83 | 341.5 |
| Mikania cordata (200mg/kg , Female) | 58.75 | 203.2 | 122.2 |
| Mikania cordata (400/ kg, Male) | 80.25 | 163.3 | 82 |

Effect of Mikania cordata on the Liver Function Test




Fig : Effect of Mikania cordata on the Liver Function Test

| Treatment Group | Pltelet 103/mm ³ (n) |
|--|------------------------------------|
| Negative Control group (Female) | 848 |
| Negative Control group (Male) | 1221 |
| Mikania cordata (200mg/kg , Female) | 1227.25 |
| Mikania cordata (400/ kg, Male) | 1360.2 |

Effect of Mikania Cordata on platelet count on the CBC (Count Blood Cell)




Fig :Effect of Mikania Cordata on platelet count on the CBC (Count Blood Cell)

| Treatment Groups | Gender | Initial body weight | Final body weight | No. of death |
|------------------------------------|--------|---------------------|-------------------|--------------|
| Normal Control | Female | 20.11±1.08 | 27.14±1.32 | 0 |
| Normal Control | Male | 22.24±1.54 | 30.19±1.93 | 0 |
| <i>Mikania cordata</i> 200mg/kg | Female | 24.21±1.06 | 29.28±.99 | 07 |
| Mikania cordata 400mg/kg | Male | 23.0±.73 | 31.4±.89 | 06 |

Table-14: Effect of methanolic extract of Mikania cordata on body weight in mice




Figure-: Graphical Presentation of Effect of methanolic extract of *Mikania cordata* on body weight in mice

Abnormalities:

During the total 90 days of chronic toxicity test I observed some abnormalities of mice. These are given below

• One mouse develop eye problem.



Figure-: Eye problem of mice

• One mouse develop tumor in neck .



Figure : Tumor in neck

• One mouse develop tumor in in neck.

In the group of 200mg/kg methalonic extract of *Mikania cordata* develop tumor. The CBC Parameters and SGPT result of that mice is given to the next page.

Table-18: CBC and biochemical parameters of tumor mice

| Parameters | Total | Neutrophil | Lymphocyte | Monocyte | Eosinophil | Basophil |
|-------------|----------|------------|------------|----------|------------|----------|
| | count of | | | | | |
| | WBC | | | | | |
| Total count | 11.32 | 23.6 | 68.5 | 4.8 | 0.5 | 0.6 |
| Reference | 3-12 x10 | 40-70% | 20-45% | 2-8% | 1-4% | 0.0-0.1% |
| value | 3/ mm3 | | | | | |

| Parameters | Total | Haemoglobin | НСТ | Mean | Mean | Mean | RDW |
|-------------|----------|-------------|------|-------------|-------------|-------------|-------|
| | Count | | | Corpuscular | Corpuscular | Corpuscular | |
| | of RBC | | | Volume | Haemoglobin | Hematocrite | |
| | | | | (MCV) | (MCH) | Cell (MCHC) | |
| Total count | 9.93 | 9.9 | 49.9 | 50.3 | 14.6 | 29.1 | 23.4 |
| Reference | 7-12 x10 | 13-17 g/dl | 40- | 43-54 | 13-18 | 31-34 | 11.6- |
| value | 6 /mm3 | | 54% | | | | 14.8 |

| Parameters | Total Count of Platelet | MPV | SGPT |
|-----------------|-------------------------|---------|----------|
| Total count | 1144 | 9.2 | 48 U/L |
| Reference value | 1000-1600 x 10 3/ mm3 | 7.2-9.2 | Up to 40 |
| | | | |

Chapter 5 Conclusion

4.5. Conclusion

As a part of our project aimed at the pharmacological evaluation of a medicinal plant, I studied the Central Nervous System activities and chronic toxicity of methanolic extract of Mikania *cordata.* The plant extract was also assessed on the central nervous system using a number of neuropharmacological experimental models in mice. The crude extract of Mikania cordata (200mg/kg, 400mg/kg) dose dependently reduces the number of peripheral locomotion, central locomotion and leaning in the open field test. The reduction is significant when it is compared to negative control. The effect of the extract is comparable to that of the standard drug, Diazepam 1mg/kg. The reference drug is found slightly potent than the extract. The crude extract of Mikania cordata (200mg/kg, 400mg/kg) also dose dependently reduces the number of head dipping and head poking in the hole board test. The reduction is significant when it is compared to negative control. The effect of the extract is comparable to that of the standard drug, Diazepam 1mg/kg. The reference drug is found slightly potent than the extract. The aim of the study was also to investigate the possible toxicity of the plant Mikania cordata and especially to establish the safety of the aqueous extract of this plant by focusing on its chronic toxicity in mice. For finding chronic toxicity several tests are done such as CBC (Cell Blood count) test, Hepatic enzyme test . CBC test and hepatic enzyme test are done by hematological machine and histological studies by microscopic test. The results of several widely accepted protocols would suggest that there were positive modulations in all the parameters of study in the Mikania cordata extract which significant difference were found in RBC and different count of RBC, WBC & different count of WBC values of treated mice. The result shows that increase toxic effect by increase dose such as (200 & 400) mg/kg and decrease cell count values and also increase SGPT value.

Reference

Reference

Agra, MF. Silva, KN. Basílio, IJLD. França, PF. Barbosa, JM., (2008), "Survey of medicinal plants used in the region Northeast of Brazil", *Rev Bras Farmacogn*, vol. 18, pp. 472-508.

Aguinaldo, AM. Padolina, WG. Abe, F. Yamauchi, T., (2003), "Flavonoids from *Mikania cordata*", *Biochem Syst Ecol*, vol. 31, pp. 665-668.

Ahmed, M. Rahman, MT. Alimuzzaman, M. Shilpi, JA., (2001), "Analgesic sesquiterpene dilactone from *Mikania cordata*", *Fitoterapia*, vol. 72, pp. 919-921.

Alberts, B., (2012), "Table 22-1 Blood Cells", Molecular Biology of the Cell, NCBI Bookshelf.

Ali, S. Islam, S. Rahman, M. Islam, R. Sayeed, MA. Islam, R., (2011), "Antibacterial and cytotoxic activity of ethanol extract of *Mikania cordata* (Burm.F.) B.L. Robinson leaves", *J Basic Clin Pharm*, vo. 2, pp. 103-107.

Bedi, G. Touzibo, ZFN. Guessan, TY. Chalchai, JC., (2003), "Chemical constituents of the essential oil of *Mikania cordata* (Burm.f.) B.L. Robinson from Abidjan (Ivory Coast)", *J. Essent. Oil Res*, vol. 15(3), pp. 198-9.

Bedoya, L.M.P. Bermejo and M.J. Abad, (2009)Anti-infectious activity in the cistaceae family in the *Iberial Peninsula*. Mini Reviews in Medicinal chemistry,9(5): 519-525

Bennett, JH., (2011), *The Employment of the Microscope inMedical Studies*, Stewart, Edinburgh, pp. 1841.

Bhattacharya, S. Pal, S. Chaudhuri, AKN., (1988), "Neuropharmacological studies on *Mikania cordata* root extract". *Planta Med*, vol. 54, pp. 483-487

Bishayee, A. and Chatterjee, M. (1994), "Anticarcinogenic biological response of *Mikania cordata*: reflections in hepatic biotransformation systems", *Cancer Lett*, vol. 81, pp. 193-200.

Boissier, JR. and Simon, P. (1964), "Dissociation de deux composantes dans le comportement d'investigation de la souris", *Arch Int Pharmacodyn*, vol. 147, pp. 372–87.

Bonita, JS. Mandarano, M. Shuta, D. Vinson, J., (2007), "Coffee and cardiovascular disease: *in vitro*, cellular, animal, and human studies", *Pharmacol Res*, vol. 55, pp. 187-198.

Boyer, J. and Liu, RH,. (2004), "Apple phytochemicals and their health benefits", *Nutr J*, vol. 3, pp. 5.

Bohlmann, F. Adler, A. King, RM. Robinson, H., (1982), "Entlabdanes from *Mikania alvimii*", *Phytochemistry*, vol. 21, pp. 173-176.

Cragg, GM. Grothaus, PG. Newman, DJ., (2009), "Impact of natural products on developing new anti-cancer agents", *Chem Rev*, vol. 109, pp. 3012-3043.

Chowdhury, NS. Alam, MB. Zahan, R. Sultana, S. Nahar, K. Haque, ME., (2011), Antimicrobial and toxicity studies of different fractions of the aerial parts of the *Mikania cordata*, *Int. J. of Pharm. & Life Sci*, vol. 2(3), pp. 592-598.

Facey, PC. Peart, PC. Porter, RBR. (2010), "The antibacterial activities of mikanolide and its derivatives", *W Indian Med J*, vol. 59, pp. 249-252.

Gaillard, Y. and Pepin, G., (1999), Poisoning by plant material: review of human cases and analytical determination of main toxins by high-performance liquid chromatography- (tandem) mass spectrometry, *Journal of. Chromatography*, vol. **733**, pp. 181-229.

Ganong, William, F., (2003), *Review of medical physiology*, (21th eds.), New York: Lange Medical Books/McGraw-Hill, pp. 518

Gasparetto, JC. Campos, FR. Budel, JM. Pontarolo, R., (2010), "*Mikania glomerata* Spreng. e *M. laevigata* Sch. Bip. ex Baker, Asteraceae: estudos agronômicos, genéticos, morfoanatômicos, químicos, farmacológicos, toxicológicos e uso nos programas de fitoterapia do Brasil", *Rev Bras Farmacogn*, vol. 20, pp. 627-640.

Gasparetto, JC. Pontarolo, R. Francisco, TMG., (2012), *Mikania glomerata* and *M. laevigata*: Clinical and Toxicological Advances, Toxicity and Drug Testing, Intech.

Ghani, A. (2003), *Medicinal Plants of Bangladesh with Chemical Constituents and Uses*, (2nd edition), Asiatic Society of Bangladesh: Dhaka.

Gupta, BD. Dandiya, PC. Gupta, ML., (1971), "A Psycho-pharmacological Analysis of Behavior in Rat", *Japan J Pharmacol*, vol. 21, pp. 293-298

Hajdu, SI., (1998), The discovery of Trichomonasvaginalis, Act Cytologica, Vol. 42, pp. 1075.

Hall, CS. Larsen, HO. Pouliot, M., (2012), "People, plants and health: a conceptual framework for assessing changes in medicinal plant consumption", *Journal of Ethnobiology and Ethnomedicine*, vol. 8, pp. 43.

Holm, LG. Plucknett, DL. Pancho, JV. Herberger, JP., (1977), *The world's worst weeds: distribution and biology*, East-West Center/University Press of Hawaii, pp. 609.

Howland, RD., Mary, MJ., (2006), *Lippincott's Illustrated Reviews Pharmacology*.(3rd eds.), Chester: Lippincott Raven Publishers. pp. 91-196.

Hussain, MS. Fareed, S. Ansari, S. Rahman, MA. Ahmad, IZ. Saeed, M. (2012), "Current approaches toward production of plant secendory metabolites", *Journal of Pharmacy and Bioallied Sciences*, vol. 4(1), pp.10-20.

Jelkmann, W., (2004), Molecular biology of erythropoietin, Intern Med, Vol. 43, pp. 649–659.

Johnston, DE., (1999), "Special considerations in interpreting liver function tests", *Am Fam Physician*, Vol. **59** (8), pp. 2223–2230.

Loomis, TA. and Hayes, AW., (1996), *Loomis's essentials of toxicology*, (4th eds.), California, Academic press, pp. 208-245

Martin, P., (2011), Approach to the patient with liver disease. Goldman, L. Schafer, AI., (24th eds), *Cecil Medicine*, Philadelphia, Pa: Saunders Elsevier; chap 148.

Maton, A. Jean, H. McLaughlin, C.W. Warner, M.Q. Lattart, D. Wright, J.D., (1993), *Human Biology and Health*, Englewood Cliffs, New Jersey, Prentice Hall.

Mc.Clatchey. Kenneth, D. (2002), *Clinical laboratory medicine*, Lippincott Williams & Wilkins, pp. 288.

Mengel, Mark, B. Schwiebert, L. Peter, (2005), *Family medicine: ambulatory care & prevention*, McGraw-Hill Professional, pp. 268.

Nunez, CV. Amêndola, MC. Lago, JHG. Roque, NF., (2004), "Diterpene acids from *Mikania sp.* nov (Asteraceae)", *Biochem Syst Ecol*, vol. 32, pp. 233-237.

Nyblom H, Berggren U, Balldin J, Olsson R., (2004), "High AST/ALT ratio may indicate advanced alcoholic liver disease rather than heavy drinking", *Alcohol Alcohol*. Vol. **39** (4), pp. 336–339.

Ohl, F. and Fuchs, E., (1999), "Di.erential e.ects of chronic stress on memory processes in the tree shrew", *Cognitive Brain Research*, vol. 7, pp. 379–87.

Ohl, F. Oitz, MS. Fuchs, E., (1998), "Assessing cognitive functions in tree shrews: visuo-spatial and spatial learning in the home cage", *Journal of Neuroscience Methods*, vol. 81, pp. 35–40.

Oliveira, PA. Turatti, ICC. Oliveira, DCO., (2006), "Comparative analysis of triterpenoids from *Mikania cordifolia* collected from four different locations", *Rev Bras Cienc Farm*, vol. 42, pp. 547-552.

Pascoe, D., (1983), *Toxicology*, England, London, Edward Arnold limited, pp. 1-60.

Patar, AA. and Yahaya, BH., (2012), "The Analysis of Aquoues and Ethanolic Extracts of Malaysian Mikania Cordata Leaves towards the Potential for Medicinal Substances", *European Journal of Scientific Research*, Vol.73(4), pp. 434-440.

Paul, N. Roy, R. Bhattacharya, S. Biswas, M., (2012), "Acute and sub-chronic toxicity study of *Cocos nucifera* leaf extracts in mice", *Journal of Advanced Pharmacy Education & Research*, vol. 2 (2), pp. 74-81.

Pereira, NA. Pereira, BMR. Nascimento, MC. Parente, JP. Mors, WB. (1994), "*Pharmacological screening of plants recommended by folk medicine as anti-snake venom*. IV. Proction against jararaca venom by isolated constituints", *Planta Med*, vol. 60, pp. 99-100.

Philip, C. and Burcham, (2014), *An Introduction to Toxicology*, Target organ toxicity: liver & kidney, Hepatotoxicity, New York: Lange Medical Books/McGraw-Hill, pp. 155.

Poole, A. and Leslie, GB., (1989), *A practical approach to toxicological investigations*, (1st eds.), Great Britain. Cambridge University press, vol. 2, pp. 30-117.

Pratt, DS., (2010), Liver chemistry and function tests, Feldman, M. Friedman, LS. Brandt, LJ., (9th eds), *Sleisenger and Fordtran's Gastrointestinal and Liver Disease*, Philadelphia, Pa: Saunders Elsevier; chap 73.

Prevost, G. Coulomb, H. Lavergne, O. Lanco, C. Teng, BP., (2002), Preparation of pharmaceutical compositions containing mikanolide, dihydromikanolide or an analog there of combined with another anticancer agent for therapeutic use in cancer treatment, PCT Int. Appl.

Purves, William, K. David, S. Gordon, H. Orians, H. Craig, H., (2004), *Life: The Science of Biology*, (7th eds.), Sunderland, Mass: Sinauer Associates, pp. 954.

Ramsay, G., (1998), Commercial biosensors, John Wiley & Sons, Inc, New York.

Robert, BT. Frederic, M. Timmons, Michael, J., (2006), *Human anatomy*, (5th eds.), San Francisco: Pearson/Benjamin Cummings, Pp. 529.

Schmidt,B.d.M. Ribnicky, A.Poulev,S. Logendra,W.T. Cefalv and I Raskia, (2008), A natural history of botanical therapeutics metabolism,57 (Suppl 1): S3-9

Skibola, CF. Smith, M.T., (2000), Potential health impacts of excessive flavonoid intake, *Free radical biology & medicine*, vol. **29**, pp. 375-383.

Tomlinson, TR. Akerele, O., (1998), *Medicinal plants their role in health and biodiversity*, Philadelphia, University of Pennsylvania press, pp. 29-40

Tønnesen, H. Hejberg, L. Frobenius, S. Andersen, J., (1986), "Erythrocyte mean cell volume--correlation to drinking pattern in heavy alcoholics", *Acta Med Scand*, Vol. **219** (5), pp. 515–518.

Timbrell, J., (2002), *Introduction to toxicology*, (3rd eds.), London, Taylor & Francis, pp. 163-179.

Varalakshmi, KN. Sangeetha, CG. Samee, US. Irum, G. Lakshmi, H. Prachi, SP., (2011), "In Vitro Safety Assessment of the Effect of Five Medicinal Plants on Human Peripheral Lymphocytes", *Tropical Journal of Pharmaceutical Research*, vol. 10 (1), pp. 33-40.

Vidal, LHI. Souza, JRP. Fonseca, EP. Bordin, I., (2006), "Qualidade de mudas de guaco produzidas por estaquia em casca de arroz carbonizada com vermicomposto", *Hortic Bras*, vol. 24, pp. 26-30.

Williamson, EM. Okpado, DT. Evans, FJ., (1996), *Selection, preparation and pharmacological evaluation of plant material. England*, John Wiley& sons, pp. 1-25.

Annexure

| List of Abbreviation | Full Meaning | | |
|----------------------|---|--|--|
| ALT | Alanine Transaminase | | |
| AST | Aspartate Transaminase | | |
| ALP | Alkaline Phosphatase | | |
| ANOVA | One-way Analysis of Variance | | |
| CBC | Complete Blood Count | | |
| СМС | Carboxy Methyl Cellulose | | |
| CNS | Central Nervous System | | |
| НСТ | Hematocrit | | |
| ICDDR, B | International Centre for Diarrhoeal Disease and Research, | | |
| | Bangladesh | | |
| LFTs or LFs | Liver Function Tests | | |
| МСН | Mean Corpuscular Hemoglobin | | |
| МСНС | Mean Corpuscular Hemoglobin Concentration | | |
| MCV | Mean Cell Volume | | |
| NCCAM | National Center for Complementary & Alternative | | |
| | Medicine | | |
| PNS | Peripheral Nervous System | | |
| RBC | Red Blood Cell | | |
| RDW or RCDW | Red Blood Cell Distribution Width | | |
| RPM | Rotation Per Minute | | |
| SALP | Serum Alkaline Phosphatase | | |
| SEM | Standard Error Mean | | |
| SGOT | Serum Glutamate Oxaloacetate Transaminase | | |
| SGPT | Serum Glutamate Pyruvate Transaminase | | |
| SPSS | Statistical Package for the Social Science | | |
| WBC | White Blood Cell | | |